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Erythropoietin (EPO) has potent neuroprotective/neuroregenerative properties in 
various forms of experimental autoimmune encephalomyelitis (EAE), i.e. established 
rodent models of acute multiple sclerosis (MS), and in patients suffering from chronic 
progressive MS. However, the mechanisms of EPO action in these conditions is still 
not clear. In particular, studies on potential effects of EPO on 
oligodendrocytes/myelin in the absence of immune-inflammatory components, which 
are characteristic for acute MS but not for the chronic progressive state of the 
disease, are lacking. Therefore, in this PhD thesis, the cuprizone mouse model was 
employed to investigate the effect of EPO on toxic demyelination. This model allows 
investigation of myelination processes independent of T-cell mediated inflammation. 
Feeding of mice with 0.2% cuprizone mixed into ground chow results in 
demyelination of the corpus callosum, whereas withdrawal of the toxin leads to 
spontaneous remyelination. The hypothesis of the present thesis was that EPO 
modulates both, cuprizone-induced demyelination and the remyelination upon toxin-
withdrawal. Two study designs were chosen to investigate the effects of EPO in a 
clinically most relevant manner: (1) EPO treatment was started immediately after 
cessation of 6 weeks of cuprizone feeding, i.e. at the time point of full damage and 
initiation of recovery/remyelination, or (2) EPO was given after 3 weeks of toxin 
application and continued for 3 weeks until cessation of cuprizone feeding to catch 
the demyelination phase. For both study parts, a 'double-blind' (for food/injections), 
placebo-controlled, longitudinal 4-arm design, using 8 week old male C57BL/6 mice, 
was applied. Target parameters included behavioral analyses, magnetic resonance 
imaging, and histology, as well as measurement of protein and mRNA levels. The 
cuprizone mouse model emerged as a highly variable animal model, making deeper 
mechanistic analyses of EPO effects difficult. Despite these limitations and a lack of 
clear effects of EPO on remyelination, EPO showed surprisingly distinct results when 
applied during the demyelination phase. Immediately after termination of cuprizone 
feeding, EPO revealed beneficial effects on vestibulomotor function/coordination, 
magnetic resonance imaging readouts and inflammation, as reflected by the number 
of microglia in the corpus callosum. Importantly, for the first time, EPO was found to 
reduce axonal degeneration in brain white matter tracts. These findings are of high 
relevance with respect to novel treatment strategies for demyelinating diseases such 





My PhD thesis is based on two projects, which both resulted in first author 
publications enclosed in the supplement of this thesis. In the first paper, 
“Erythropoietin attenuates neurological and histological consequences of toxic 
demyelination in mice,” consequences of cuprizone-induced demyelination and the 
effect of erythropoietin (EPO) as a potential treatment strategy on these parameters 
were investigated. The second study, “A myelin gene causative of a catatonia-
depression syndrome upon aging,” analyzed the pathophysiological consequences of 
an altered expression of the myelin gene 2‟,3‟-cyclic nucleotide 3'-phosphodiesterase 
(CNP). Additionally, two co-author publications are enclosed.  
In this PhD thesis, I would like to focus on my main project analyzing the effect of 
EPO on de- and remyelination processes. I will elaborate mainly upon unpublished 
data of this project and include the published data as well.  
 
 
1.1 Cuprizone  
 
The discovery of cuprizone (oxalic acid bis(cyclohexylidene hydrazide) as an agent 
with copper chelating properties dates back to the 1950s. Gustav Nilsson 
demonstrated that cuprizone reacts with copper to produce a stable blue color and 
that this reaction was very sensitive even at low concentrations of copper (Nilsson, 
1950). The technique was further described as a tool to detect copper levels in pulp 
and paper, in iron, steel and ferrous alloys and even in serum (Peterson & Bollier, 
1955; Wetlesen, 1957). The cuprizone-copper complex has a molar absorbance at 
595 nm and is stable at a pH of 7-9 (Benetti et al, 2010; Messori et al, 2007; 
Peterson & Bollier, 1955). However, the exact chemical property of the cuprizone-
copper complex that results in an intense blue color is still not completely understood 
and is described to be rather complex. On one hand, it is suggested that cuprizone in 
the cuprizone-copper complex stabilizes copper (III); on the other hand, it is shown 
that only copper (II) is present in the cuprizone-copper complex (Benetti et al, 2010; 






1.2 The cuprizone animal model 
1.2.1 Early history and development of the animal model 
The initial idea of the cuprizone model was to mimic copper deficiency in animals. 
Copper is an essential trace element and it was observed that copper deficit in the 
food of pregnant ewes can lead to neurological impairments and lesions of 
demyelination in offspring. However, the proper animal model to study the cause and 
pathogenesis of the disease was missing (Carlton, 1966). In 1966 Carlton had the 
idea to use copper-chelating agents in experimental animals to mimic a copper 
deficiency and to study its consequences (Carlton, 1966). He used weanling male 
mice or pregnant mice and fed them cuprizone in a dose of 0.1% or 0.5% mixed into 
a chicken mash diet for 7 weeks. Additionally, he analyzed the effect of 0.5% 
cuprizone supplemented with different concentrations of copper sulfate. The lower 
dose of cuprizone resulted in slightly reduced growth, cerebellar edema and 
demyelination in weanling mice but did not affect pregnancy. However, high-dose 
cuprizone led to an increased mortality in the offspring of pregnant mice and a severe 
decrease in growth, increased mortality, paresis, cerebellar edema, demyelination 
and hydrocephalus in weanling mice. In general, supplementation of copper sulfate 
did not change the effect of cuprizone. After this first report of cuprizone application 
in mice, several studies followed to further characterize the model. The first two 
subsequent studies were performed by Carlton himself, wherein he demonstrated 
that spongy degeneration, astrogliosis and hydrocephalus were present at early 
stages (weeks 2-5) of cuprizone intoxication; myelin loss was first present at week 9. 
Moreover, it was seen that with increasing age, mice were less susceptible to 0.5% 
cuprizone (Carlton, 1967). Interestingly, it was observed that rats and guinea pigs 
were less susceptible to cuprizone than mice, showing a difference between species 
(Carlton, 1969; Love, 1988). Other studies confirmed previous findings in cuprizone-
fed mice of an elevated mortality rate, hydrocephalus, status spongiosus and 
reactive/hypertrophic astrocytes, which were mainly studied in cerebellar white 
matter but described as well e.g. in brain stem, cerebellar cortex, hippocampus and 
corpus callosum (Blakemore, 1972; Kesterson & Carlton, 1971; Pattison & Jebbett, 
1971; Pattison & Jebbett, 1973; Suzuki & Kikkawa, 1969; Venturini, 1973). It was 
specified that the histopathological changes occured bilaterally (Pattison & Jebbett, 
1971). The formation of vacuoles in myelin sheaths and swollen astrocytes were 
thought to be possible causes of spongy degeneration in the brain stem and both 
 1.Introduction 
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cerebral and cerebellar white matter (Suzuki & Kikkawa, 1969; Venturini, 1973). 
Additionally, enlarged and giant mitochondria in the liver were found in the same two 
studies, revealing toxic adverse effects in the peripheral system under cuprizone 
treatment. Meanwhile, Pattison and Jebbett were the first to describe potential for 
recovery in the cuprizone model. Mice of the BSVS strain were repeatedly fed with 
0.5% cuprizone, followed by a normal food diet after the first and second “cuprizone-
cycle”. They found all known histopathological changes during the first and second 
cycle of cuprizone feeding. In both periods of normal food, mice recovered from the 
previous symptoms and only slightly enlarged ventricles could still be seen at the end 
of the recovery phase (Pattison & Jebbett, 1973). This finding was important for 
future studies. Up until this point, all investigators had mainly focused on the aspect 
of spongy degeneration, a common finding in neurological disorders like scrapie 
disease. Blakemore was the first to put attention on the degeneration of 
oligodendrocytes and reported an increase of microglia upon cuprizone intoxication 
(Blakemore, 1972). With electron microscopy he observed degenerated 
oligodendrocytes early after cuprizone intoxication, followed by demyelinated axons 
and the appearance of remyelinating oligodendrocytes in several brain regions. Since 
then, degeneration of oligodendrocytes became the main focus in the cuprizone 
model and it developed into a model which allows investigation of de- and 
remyelination processes. 
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Table 1: Early history and development of the cuprizone model. 
Author Year Species Experimental set-up Results Remarks 
Carlton 1966 Weanling male 
mice 
Male weanling mice:  
7 week feeding with  
Trial 1: 0.1% cuprizone 
Trial 2: 0.5% cuprizone 
Trial 3: 0.5% cuprizone + 
copper sulfate 
Trial 1: Slightly reduced growth; cerebellar edema and demyelination. 
Trial 2: Severely decreased growth; increased mortality; weakness in 
mice, paresis evident; cerebellar edema and demyelination; 
hydrocephalus.  







Pregnant mice Pregnant mice:  
cuprizone (0.1 or 0.5%) 
feeding started on day 3 or 
9 of gestation ± copper 
sulfate 
0.1% cuprizone did not affect pregnancy. 
0.5% cuprizone: no delivery when feeding started on day 3; increased 
percentage of nonviable young when feeding started at day 9; 
increased number of viable young by supplementation of 130ppm 
copper.  




Trial 1: Feeding of 
weanling mice with 
cyclohexanone & 
oxaldihydrazide (chemical 
precursors of cuprizone) for 
7 weeks 
Trial 2: Supplementation of 
several vitamins and a 
vitamin mixture to 0.5% 
cuprizone diet for 7 weeks 
Trial 3: Supplementation of 
Diurill to 0.5% cuprizone 
diet for 7 weeks 
Trial 4: Supplementation of 
130ppm/260ppm copper to 
0.2% cuprizone diet for 7 
weeks 





Trial 2: A vitamin mixture, riboflavin and vitamin A supplement reduced 
the mortality rate; no further effects. 
 
 
Trial 3: No effect of Diurill supplement. 
 
 








4-8 week old male 
mice 
Trial 5: 4 or 8 week old 
male mice received 0.5% 
cuprizone diet for 8 weeks 
Trial 6: Time scale 
experiment, feeding of 
0.3% cuprizone and weekly 
analysis of mice 
Trial 5: With increasing age at the start of cuprizone feeding fewer mice 
developed hydrocephalus. 
 
Trial 6: Spongy degeneration observed after 2 weeks; astrogliosis 
occurred at week 4; hydrocephalus observed at week 5; myelin loss 
apparent after 9 weeks. 
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Rats: Feeding with 0.1, 0.5, 
1 or 1.5% cuprizone over 8 
weeks 
 
0.5% cuprizone: increased mortality rate; enlarged and swollen 
astrocytes, edema and status spongiosus in several brain regions.  
1 & 1.5% cuprizone: Death of half of the rats in weeks 3-4. No 
hydrocephalus observed. 
Rats and guinea 
pigs used; 
effects in 
general milder  
than in mice Male albino guinea 
pigs 
Guinea pigs: Feeding with 
0.5, 0.75 or 1% cuprizone 
over 21 weeks 
0.75% cuprizone: higher mortality rate.  






Webster male mice 
Feeding of 0.5% cuprizone 
up to 3 weeks 
CNS: Status spongiosus (most prominent in brain stem and cerebellar 
white matter) caused by formation of vacuoles in myelin sheaths and in 
the cytoplasm of glial cells. 





1970 Weanling Swiss 
albino male mice 
Feeding of 0.3, 0.5 or 
0.75% cuprizone up to 8 
weeks 
Induction of hydrocephalus occurred secondary to stenosis of the 
aqueduct of Sylvius. May have resulted due to pressure exerted by the 




1971 4-6 week old BSVS 
mice 
Feeding of 0.5% cuprizone 
up to 60 days 
Increased mortality rate; extracellular vacuolation and hypertrophic 




1971 Weanling Swiss 
albino male mice 
Feeding of 0.3% cuprizone 
up to 8 weeks  
Status spongiosus (prominent in thalamus, cerebellar medulla, reticular 
formation, corpus callosum, cerebellar peduncle, internal capsule, pes 
pedunculi, medial geniculate body, cerebellar folia); edema (cerebral 
cortex, basal ganglia, hippocampus); reactive astrocytes (cerebral 
cortex, putamen, hippocampus, caudate putamen, corpus callosum, 
ventral thalamic nucleus, cerebellar folia, cerebellar nucleus).  
Increased activity of several enzymes in astrocytes, most prominently: 




1973 3-6 week old BSVS 
female mice 
Feeding of 0.5% cuprizone 
1, 2, 3, 4, or 6 weeks 
followed by 60 days with 
normal food 
 
Confirmation of previous studies: mortality rate increased; older mice 
less vulnerable to cuprizone.  
After 60 day recovery: no changes in mice fed for 1, 2 or 3 weeks with 
cuprizone before; rarefaction of tissue in vicinity to slightly dilated 






Repeated feeding: 37 days 
cuprizone followed by 52 
days normal food, again 
cuprizone for 38 days 
followed by 52 days normal 
food 
Repeated feeding: Spongiform vacuolation, dilatation of ventricles and 
increased number of astrocytes and microglia after 37days cuprizone, 
after 34 days on normal diet only slightly dilated ventricles detected. 
Histopathology in second cuprizone cycle similar to the first, no changes 
after second cycle of withdrawal of cuprizone. Fast physical recovery 
after cuprizone withdrawal. 
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Venturini 1973 30 day old Swiss 
male mice 
Feeding with 0.5% 
cuprizone or copper-
chelated cuprizone up to 4 
weeks 
Growth retardation; impaired motility of hind limbs; status spongiosus 
(brain stem and cerebral and cerebellar white matter) due to vacuoles 
within the myelin sheaths and swollen astrocytes. Enlarged and giant 
mitochondria in liver cells.  
In brain and liver: Reduced activity of monoamine oxidase and 
cytochrome oxidase; increased activity of succinate dehydrogenase.  
Decreased dry weight of brains after cuprizone treatment; increased 
Na
+




 levels in brain tissue. Feeding of 
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1.2.2 The cuprizone model of demyelination and remyelination 
The first discovery of cuprizone-induced degeneration of oligodendrocytes and 
demyelination led to further characterization of the model. The first studies focused 
on the superior peduncle and found that feeding of weanling ICI male mice with 0.5% 
cuprizone resulted in a distinct time course of demyelination which started at week 2, 
peaked at week 5 and stayed constant until week 8; morphological changes in 
astrocytes and microglia were observed (Blakemore, 1973a). It was seen that 
withdrawal of cuprizone from the diet for 6 weeks led to remyelination, however, 
myelin sheaths were thinner compared to control mice (Blakemore, 1973b). Similar 
results from others confirmed the potential of remyelination by withdrawal of 
cuprizone (Blakemore, 1974; Ludwin, 1978) and made the model even more 
interesting to study not only the aspect of demyelination but also remyelination. 
However, some variations in the time course of de- and remyelination between 
different studies could be the result of a different susceptibility of older mice and 
different mouse strains to cuprizone, as well as variations in the cuprizone 
concentrations used (Blakemore, 1974; Carlton, 1967; Ludwin, 1978). Since it was 
discovered that 8-10 week old C57BL/6 mice fed with 0.2% cuprizone showed clear 
demyelination of the corpus callosum, but did not show liver toxicity, this strain was 
preferentially used in future studies (Hiremath et al, 1998). Moreover, the corpus 
callosum became the main target region for the analysis of myelination (for detailed 
descriptions of the studies please see Table 2). A generally important characteristic 
of the cuprizone model is to find an intact blood-brain-barrier (BBB) (Bakker & 
Ludwin, 1987; Kondo et al, 1987). 
 
1.2.2.1 Characterization of cuprizone-induced damage 
Demyelination and remyelination in the corpus callosum are mainly studied 
histologically using Luxol Fast Blue-periodic acid Schiff (LFB-PAS) and 
immunohistochemically using different markers for myelin proteins (e.g. myelin basic 
protein (MBP), proteolipid protein (PLP)). These techniques allow a subjective 
(observer blinded) semi-quantitative analysis by rating the staining on a scale of 
severity of demyelination. A more precise but labor intensive analysis of myelin via 
electron microscopy is less frequently performed. Consequences of cuprizone 
intoxication on myelin in the corpus callosum are studied after acute (6 weeks) or 
chronic (12-16 weeks) application. Figure 1 summarizes the morphological and 
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cellular changes in the corpus callosum after acute cuprizone feeding as described in 
detail below. Demyelination after acute administration of cuprizone starts at week 3 
and is almost complete in weeks 5-6 (Gao et al, 2000; Hiremath et al, 1998; Mana et 
al, 2006; Matsushima & Morell, 2001; Merkler et al, 2005; Morell et al, 1998; 
Remington et al, 2007). Interestingly, intrinsic remyelination already starts at week 6 
of cuprizone feeding (Irvine & Blakemore, 2006; Mason et al, 2000; Mason et al, 
2001a). Long-term feeding of cuprizone induces episodic de- and remyelination 
within the corpus callosum, showing the potential of intrinsic remyelination by weeks 
6 and 12 even during continuous application of cuprizone (Mason et al, 2001a). 
Withdrawal of cuprizone after acute demyelination leads to almost complete 
remyelination on an immunohistochemical level over 6 weeks, whereas remyelination 
after chronic cuprizone treatment leads to a slower and incomplete remyelination 
even after 12 weeks (Armstrong et al, 2006; Crawford et al, 2009; Lindner et al, 
2008; Mason et al, 2001a; Matsushima & Morell, 2001; Morell et al, 1998). Based on 
electron microscopy, however,  it is known that the recovery of myelin even 6 weeks 
after acute demyelination is also still incomplete (Crawford et al, 2009; Lindner et al, 
2008; Merkler et al, 2005). During demyelination the expression levels of several 
myelin genes are altered; MBP, myelin associated glycoprotein (MAG), ceramide 
galactosyl transferase (CGT), and PLP are gradually downregulated starting at week 
1 and reaching a minimal expression level in weeks 2-4. Interestingly, re-expression 
of the genes starts already at week 5, and at the beginning of the recovery phase, 
the gene expression is even higher compared to controls (Gao et al, 2000; Morell et 
al, 1998).  
Oligodendrocytes are the myelinating cells in the central nervous system and of 
special interest for evaluation in the cuprizone model. The characterization of the 
effect of cuprizone on oligodendrocytes is mainly based on immunohistochemistry 
using the antibodies: glutathione S-transferase-pi (GST-pi), adenomatous polyposis 
coli (APC) CC-1 and Nogo-A, for mature oligodendrocytes and nerve/glial antigen 2 
(NG2) or platelet-derived growth factor receptor-alpha (PDGFRα) for precursor 
oligodendrocytes. The number of mature oligodendrocytes gradually decreases upon 
acute cuprizone intoxication reaching the lowest levels in weeks 5-6 and an intrinsic 
reappearance of oligodendrocytes is observed at week 6. After 2 weeks of 
remyelination, oligodendrocytes are already further increased and reach control 
levels until week 10. The number of precursor oligodendrocytes increases until 
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weeks 3-5 and is followed by a slight decrease. However, the overall number 
remains elevated even at week 10 of recovery (Arnett et al, 2001; Crawford et al, 
2009; Gudi et al, 2009; Mason et al, 2000; Matsushima & Morell, 2001). Chronic 
demyelination leads to a depletion of mature oligodendrocytes until weeks 5-6, 
however, a population of cells reappears until week 12 of cuprizone feeding. In this 
condition, precursor oligodendrocytes increase until week 5 but are progressively lost 
upon further intoxication (Mason et al, 2004).  Oligodendrocytes are mainly depleted 
by apoptosis (Mason et al, 2000; Mason et al, 2004). Astrocytes are gradually 
upregulated and hypertrophic during acute demyelination and stay at a high level in 
the recovery phase (Crawford et al, 2009; Gudi et al, 2009; Hiremath et al, 1998). A 
similar pattern is observed under chronic conditions (Lindner et al, 2009). The 
number of microglia is highly upregulated with a peak in weeks 5-6 during acute and 
chronic demyelination. Removal of cuprizone after 6 weeks leads to a fast decline to 
control levels 2-5 weeks later (Arnett et al, 2001; Gudi et al, 2009; Hiremath et al, 
1998; Lindner et al, 2009; Mason et al, 2004; Merkler et al, 2005; Morell et al, 1998). 
During chronic exposure, microglia decline but stay elevated after week 6, and during 
a following recovery phase, microglia are present at a very low level (Lindner et al, 
2009; Mason et al, 2004). It is suggested that microglia increase their phagocytic 
activity during cuprizone-induced demyelination (Voss et al, 2012). Acute axonal 
degeneration (investigated with the antibody amyloid precursor protein (APP)) is 
present 3-6 weeks after cuprizone intoxication (Crawford et al, 2009; Lindner et al, 
2009; Merkler et al, 2005; Song et al, 2005) and suggested to gradually decrease 
after weeks 3-4 (Lindner et al, 2009; Song et al, 2005). Results for an additional 
marker for axonal degeneration (Neurofilament H non-phosphorylated (SMI-32)) are 
rare and so far inconclusive (Lindner et al, 2009; Sun et al, 2006). Swollen and 
dystrophic axons are observed with electron microscopy 5-6 weeks after cuprizone 
feeding and can even be found in the first 2 weeks of recovery (Irvine & Blakemore, 
2006; Stidworthy et al, 2003). Furthermore, functional axon damage is seen by a 
conduction deficit during demyelination, which is not fully recovered by a 6 week 
remyelination period (Crawford et al, 2009).  
Cuprizone-induced demyelination is not restricted to the corpus callosum and 
additionally present in the cortex, hippocampus and cerebellum (Groebe et al, 2009; 
Hoffmann et al, 2008; Koutsoudaki et al, 2009; Norkute et al, 2009; Skripuletz et al, 
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2008; Skripuletz et al, 2010b). Please find a detailed summary of the main cuprizone 




























                          Figure 1: Overview of the morphological and cellular changes  
                            during acute cuprizone feeding for 6 weeks and within a 6 week 
                            recovery period.
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Table 2: The cuprizone model of de- and remyelination. Studies are sorted chronologically within the subgroups. Antibodies and/or methods used are given in 
brackets. 
Author Year Species Experimental set-up Results Remarks 
Blakemore  1972 Weanling albino 
ICI male mice 
 
Feeding of 0.5% cuprizone 
for 1, 2, 4 and 5 weeks  
From 1
st
 week on: Astrocytosis (cerebral cortex, caudate-putamen, 
thalamus, midbrain); status spongiosus (internal capsule, anterior 
commissure, thalamus, midbrain, cerebellum, white matter of 
cerebellum); degenerated oligodendrocytes (cerebral cortex and white 
matter). Increased number of microglia at week 3. Remyelinating 
oligodendrocytes and a large number of demyelinated axons present at 
week 5. 









ICI male mice 
Feeding with 0.5% cuprizone 




 week on: Degenerated oligodendrocytes. Demyelination 
peaked at week 5 and stayed constant until week 8; demyelination 
accompanied by morphological changes of astrocytes and microglia, 






Feeding with 0.5% cuprizone 
for 5 weeks followed by 
normal food up to 6 weeks 
Withdrawal of cuprizone from the diet: Induction of remyelination. After 
4-6 weeks almost all axons remyelinated (~ 88%). Remyelinated 
sheaths thinner, axon-fiber diameter ratio not back to control levels. 
Remyelination 
capacity 
Blakemore 1974 9 month old albino 
ICI male mice 
Feeding of 0.75% cuprizone 
up to 10 weeks followed by 
normal food up to 12 weeks  
Start of demyelination at week 7 of feeding, almost complete at week 
10. Almost complete remyelination after 6 and 12 weeks on normal diet. 
Remyelinated sheaths thinner compared to controls.  
 
Ludwin 1978 Weanling Swiss 
male mice 
Feeding of 0.6% cuprizone 
for 6-7 or up to 25 weeks. 
The 6-7 week feeding period 
was followed by normal 
feeding up to 18 weeks 
Weeks 1-4 of cuprizone: Higher mortality rate. Hydrocephalus in most of 
the mice. Degeneration of oligodendrocytes from 2 weeks on; almost 
complete demyelination at week 7, no further change in the grade of 
demyelination thereafter. Peak of phagocytic macrophages at week 5 
followed by a decrease. Reactive astrocytes and other undefined 
reactive and immature cells present at week 4. Recovery: Fast capacity 
of remyelination until week 4 but slow capacity until week 18. Myelin 
sheaths only reached ~ 50% of normal myelin thickness. 
 
Love  1988 Weanling male 
Wistar rats 
Feeding of 0.5, 1 or 2% 
cuprizone up to 15 weeks. 3 
rats fed with 0.1% cuprizone 
were returned to normal diet 
after 10 weeks. 
Feeding of 1 or 2% cuprizone: higher mortality, weakness and wasting; 
intramyelinic edema (cerebral white matter, hilum of the dentate nucleus 
and superior cerebellar peduncle), rarely degenerated 
oligodendrocytes, no demyelination. Mild axonal degeneration in sciatic 
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Analysis of the blood-brain-barrier (BBB) 
Bakker & 
Ludwin 
1987 Weanling CD1 
mice  
Feeding of 0.5-0.6% 
cuprizone over 9 weeks  
BBB proven to not be permeable by horseradish peroxidase tracer 
method & immunohistochemically using antisera to extravasated serum 





1987 3 week old Swiss-
Webster male 
mice 
Feeding of 0.5% cuprizone 
up to 9 weeks 
BBB proven to not be permeable by the horseradish peroxidase tracer 
method (cerebrum, brainstem, spinal cord). 
 
Tracer studies 
Analysis in the corpus callosum (CC) 
Hiremath et 
al. 
1998 8-10 week old 
C57BL/6J male 
mice 
Feeding of 0.1 to 0.6% 
cuprizone for 6 weeks 
Severe body weight loss with increasing cuprizone concentration. Liver 
only affected under 0.4% and 0.5% cuprizone. Complete demyelination 
(LFB, MBP) of the CC with 0.2-0.5% cuprizone at week 6. 
C57BL/6 mice 
introduced & 
analysis of the 
corpus callosum  
 
Feeding of  0.2% cuprizone 
over 6 weeks; mice were 
sacrificed weekly 
Start of demyelination at week 3; completion of demyelination at week 
6; no further detrimental toxic effects. Astrocytosis paralleled to 
demyelination; microglia/macrophages (RCA-1) appeared in the 1
st
 
week & increased further. 
Morell et al. 1998 6 week old 
C57BL/6J mice 
Feeding of 0.2% cuprizone 
up to 6 weeks followed by 
normal food up to 6 weeks  
~20% body weight loss within 1
st
 week; demyelination (LFB) in CC 
started at week 3, maximal in weeks 4-6. MBP, MAG & CGT-mRNA 
levels decreased at week 1, minimal at week 3, returned to normal 
levels until week 6; elevated expression levels at the beginning of 
recovery. Microglia (RCA-1; lysozyme) followed pattern of 
demyelination. 
 
Gao et al. 2000 8 week old 
C57BL/6 & IFN-γ 
transgenic male 
mice 
Feeding of 0.2% cuprizone 
for up to 6 weeks  
 
IFN-γ transgenic mice (very low level of IFN-γ expression): Resistant to 
cuprizone-induced demyelination in the CC; no changes on the number 
of astrocytes, microglia & apoptotic cells. MBP & PLP-mRNA levels 
decreased in weeks 2-4. IGF-1 increased. 
Role of IFN-γ in 
demyelination 
Mason et al. 2000 8 week old 
C57BL/6J male 
mice 
Feeding of 0.2% cuprizone 
up to 6 weeks followed by 
normal food up to 6 weeks 
Mature oligodendrocytes (GST-pi) almost completely depleted (largely 
by apoptosis) at week 6 and reappeared during remyelination phase. 
NG2
+
 cell proliferation in the subventricular zone and accumulation in 
the CC upon demyelination (peak at week 4). NG2
+
 cells switched from 
a bipolar to a branch-like phenotype in advance to the repopulation of 
GST-pi
+
 cells. IGF-1 expression upregulated with a peak at week 4 and 
remained elevated until week 7 (potentially involved in remyelination). 
 
Mason et al. 2001 
a 
8 week old 
C57BL/6J mice  
Feeding of 0.2% cuprizone 
up to 16 weeks or for 6 
weeks followed by normal 
food up to 6 weeks 
Long-term feeding induced episodic de- and remyelination (intrinsic 
remyelination at weeks 6 and 12); cuprizone feeding decreased axon 
diameter & thickness of myelin sheaths. 67% myelinated axons present 
at recovery week 4; average diameter of myelinated axons increased; 
myelin sheaths of remyelinated axons thinner than controls, high 
number of unmyelinated small caliber axons after recovery.  
 




2001 8-10 week old 





Feeding of 0.2% cuprizone 
up to 6 weeks 
Several cytokines up-regulated upon demyelination (TNF-α & IL-1β), 
MIP-1α and its receptor CCR-5 peaked in weeks 4-5. 
MIP-1α
-/-
 mice: Delayed onset of demyelination in the CC (LFB; EM) 
correlated with a decreased number of astrocytes and microglia/ 
macrophages (RCA-1) in the CC; TNF-α level decreased. 
 
Mason et al. 2001 
b 





Feeding of 0.2% cuprizone 
for 6 weeks followed by 
normal food for 6 weeks  
During demyelination: IL-1β/IGF-1-mRNA upregulation in wild-type 
mice; mainly microglia express IL-1β & astrocytes IGF-1 (still elevated 
during remyelination).  
IL-1β
-/-
 mice: Demyelination including depletion of mature and 
accumulation of precursor oligodendrocytes. Impaired remyelination: 
Decreased number of remyelinated axons & mature oligodendrocytes. 
NG2
+
 cells still elevated. No IGF-1
+
 cells detected in CC.  
Suggests role for 















Feeding of 0.2% cuprizone 
for 6 weeks followed by 
normal food for 4 weeks 
TNFα upregulated during demyelination in wild-type mice; TNFα
+
 cells 
co-localized with microglia (RCA-1) & astrocytes; TNFR2 but not 
TNFR1 upregulated during de-/remyelination.  
TNFα
-/-









 cells during 





decreased upon remyelination. No changes in TNFR1
-/-
 mice. 









2003 10 week old 
C57BL/6 female 
and male mice 
Feeding of 0.2% or 0.4% 
cuprizone for 5 weeks 




 week: all mice switched to 0.2% cuprizone due to the severe 
effect of 0.4% cuprizone. Caudal part of CC more susceptible to 
demyelination; cerebellar peduncle not affected. 2 weeks recovery: No 
change in G-ratio, relation of axon diameter & myelin sheath thickness 
not conclusive, swollen dystrophic axons present. High variability of all 







Mason et al. 2004 8 week old 
C57BL/6J mice 
Feeding of 0.2% cuprizone 
up to 16 weeks or for 5 
weeks followed by normal 





Chronic demyelination in CC: Ongoing apoptosis of oligodendrocytes; 
little intrinsic remyelination; progenitor oligodendrocytes (NG2) 
increased in weeks 4-5, became progressively depleted until week 12. 
Peak of microglia/macrophages (RCA-1) at week 6, remained elevated 
afterwards. Transplantation of O4
+
 oligodendrocyte progenitors at week 









2005 7-8 week old 
C57BL/6J male 
mice 
Feeding of 0.2% cuprizone 
for 6 weeks followed by 6 
weeks recovery with normal 
food 
Week 6 of cuprizone: Demyelination (LFB, EM); G-ratio increased, 
acute axonal damage (APP), astrocytes & microglia (Mac-3) increased. 
6 weeks recovery: G-ratio & astrocytes still elevated, microglia reduced. 
MRI analyses: The individual parameters T1 & T2 correlated with EM 
data. To differentiate regions of de-/remyelination, a discriminate 
function analysis using a combination of T1, T2 & MTR is necessary.  
Development of 
MRI method to 
predict the 
myelin status in 
vivo 








Feeding of 0.2% cuprizone 
for 6 weeks (young mice) & 
0.4% cuprizone for 7 weeks 
(old mice) followed by 6 or 7 
weeks on normal diet 
Demyelination similarly distributed within the CC in both age groups but 
marginally greater in young mice; evidence of intrinsic remyelination in 
young but not old mice. More severe axonal degeneration (SMI32 & 
EM) in aged mice. Significant loss of axons in aged mice at 7 & 14 
weeks. Higher number of microglia (CD11b) & astrocytes in old mice. 
Suggests aged 
mice are more 












Feeding of 0.25% cuprizone 
for 4 weeks followed by 4 
weeks recovery with normal 
food 
Increased iNOS & nNOS-mRNA levels in wild-type mice. nNOS
-/-
 vs. 
wild-type mice: Minor demyelination but slower remyelination; only 
slightly increased number of microglia (RCA-1), astrocytes, apoptotic 
cells; decreased NG2
+
 cells; decreased secretion of TNFα, IL-1β, IGF-1 
& iNOS by cuprizone. eNOS
-/-
 mice: Demyelination & cellular changes 
comparable to wild-type mice; only slightly delayed remyelination & 
reduced IGF-1 expression in cuprizone week 4. 
Suggests that 
constitutive NOS 





2006 8 week old 
C57BL/6 male 
mice 
Feeding of 0.2% cuprizone 
for 6 or 12 weeks followed by 
normal food for 6 weeks 
 
Poorer recovery after chronic vs. acute demyelination in C57BL/6 mice; 
density of mature (PLP) & precursor (PDGFRα) oligodendrocytes 
severely decreased; compromised but continued precursor proliferation 















Swiss) male mice 
FGF2
-/-
 mice susceptible to cuprizone-induced demyelination; better 
recovery rate compared to control mice; oligodendrocyte number 
returned to control levels after 6 weeks recovery. Number of precursor 
oligodendrocytes & proliferating cells not affected. 




male mice  
Feeding of 0.2% cuprizone 
up to 6 weeks followed by 
normal food for 3 weeks 
 
IFNγ had no effect on demyelination but remyelination in the CC: Lower 
number of APC
+
 cells, remyelinated axons & reduced myelin score, 
altered time course of NG2
+
 cell recruitment. Failure of remyelination 
associated with activation of the stress pathway of the endoplasmic 
reticulum. 




Mana et al. 2006 8-14 week old 
C57BL/6 &   
IFNγR
-/-
 male mice 
Feeding of 0.25% cuprizone 
for 6 weeks followed by 
normal food for 4 weeks 
Increased IFNγ expression level during cuprizone feeding in wild-type 
mice. IFNγR
-/-
 vs. wild-type mice: Demyelination slightly delayed (LFB) 
but comparable at week 6; more myelinated axons at week 4, GST-pi
+
 
cells higher at week 6; NG2
+
 cells peaked at week 3 but higher; delayed 
accumulation of microglia (RCA-1) until week 4; astrocyte number 
comparable; TNFα & IGF-1 increased (but less) during demyelination; 
faster remyelination. 
Role of IFNγ in 
contrast to study 
of Gao et al. 
Remington 
et al. 








Feeding of 0.2% cuprizone 
up to 6 weeks followed by 
normal food for 3 weeks 
Increased cell number in demyelinated CC (peak at week 4.5); majority 




), only few blood 
derived macrophages (CD45
high
). Majority of cells show activation profile 
(B7.2/CD86, B7.1/CD80, MHC class I). A subpopulation of CD11c
+
 
microglia/macrophages identified as antigen-presenting cells restricted 
to the demyelinated CC, higher activation level. Microglia expansion in 









2008 8 week old 
C57BL/6 male 
mice 
Feeding of 0.2% or 0.3% 
cuprizone for 6 weeks 
followed by normal food for 
10 weeks (just 0.3% 
cuprizone-treated mice) 
Demyelination in CC incomplete by 0.2% & complete by 0.3% cuprizone 
at week 6. 0.3%cuprizone: G-ratio increased, percentage of myelinated 
axons decreased in weeks 4-6; fast remyelination started at day 4, 
almost complete at week 2 (LFB). Different re-expression pattern during 
remyelination of PLP, CNPase, MBP & MOG. Recovery rate highest in 
weeks 1-2 of remyelination phase. 
Focus on early 
remyelination 
 






Feeding of 0.2% cuprizone 
for up to 6 weeks followed by 
normal food up to 8 weeks 
Slight upregulation of TNF-like weak inducer of apoptosis (TWEAK) & 
its receptor Fn14 during demyelination in wild-types. TWEAK
-/-
 mice: 
Slightly delayed demyelination (LFB, MBP) & accumulation of 




2009 8 week old PLP-
EGFP (C57BL/6) 
female mice 
Feeding of 0.2% cuprizone 
for 
- 1.5 weeks + 3 weeks 
recovery 
- 3 weeks + 6 weeks 
recovery 
- 6 weeks + 6 weeks 
recovery  
Gradual demyelination (CC) from weeks 1.5 to 6 (MOG); remyelination 
to normal levels in 1.5+3w & 3+6w group but incomplete in 6+6w group. 
Increase of precursor (PDGFRα) & decrease of mature (GST-pi) 
oligodendrocytes during demyelination, back to control levels in all 
remyelination groups. Microglia (CD45) increased during de- & 
remyelination. Astrocytes increased during demyelination & even higher 
upon remyelination. Functional axon damage in CC: Impaired 
amplitude, latency & refractoriness of compound action potentials even 
after remyelination (3+6w, 6+6w). Nodal protein disorganization & 
increased axonal damage (APP) at weeks 3 & 6 of demyelination & 
after remyelination (3+6w, 6+6w). Reduced G-ratio at all time points of 
demyelination & in 6+6w remyelination group. 
Remyelination 
capacity 
Gudi et al. 2009 8 week old 
C57BL/6 male 
mice 
Feeding of 0.2% cuprizone 
up to 6 weeks 
Regional differences in grey & white matter: Delayed demyelination in 
grey matter; all cell types analyzed less present & responsive in cortex 
than in CC; pattern of oligodendrocytes (Nogo-A, NG2) & astrocytes 





 cells at week 4 decline thereafter, increased number 




 (for both: CC more 
pronounced).  
Comparison of 




2009 8 week old 
C57BL/6 male 
mice 
Feeding of 0.2% cuprizone 
for: 
-  6 weeks + 6 weeks 
recovery 
- 12 weeks + 12 weeks 
recovery 
- 14 or 16 weeks + 4 weeks 
recovery 
Demyelination of the CC at 6-12 weeks. 12 week cuprizone feeding: 
Reduced remyelination rate in weeks 1-2 of recovery, almost complete 
at the end of recovery. Data about mature (Nogo-A) oligodendrocytes 
inconclusive. Start of astrocyte accumulation at week 4, stayed constant 
until the end of recovery (acute & chronic model). Peak of microglia 
(Mac-3) accumulation at week 6, decreased thereafter (acute & 
chronic). Peak of acute axonal damage (APP) in weeks 4-6 and 
remained elevated (chronic). Correlation of microglia and APP
+
 axon 
number. SMI-32 present at week 8, most prominent at week 16 of 
chronic demyelination, not decreased during recovery. 
Axonal 
degeneration  
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Feeding of 0.2% cuprizone 




 mice: relatively resistant to cuprizone toxicity; decrease of 
mRNA levels of oligodendrocytes, only moderate loss of mature (GST-
pi) & progenitor (PDGFRα) oligodendrocytes, no apoptosis; Cxcr2-
positive neutrophils from bloodstream identified to be necessary for 
cuprizone-induced demyelination.  
 
Voß et al. 2012 8 week old 
C57BL/6 male 
mice 
Feeding of 0.2% cuprizone 
for 5 weeks followed by 
normal food for 1 week 
 
Peak of microglia (RCA-1) at week 3 in CC & cortex; new cell 
population with macrophage expression pattern appeared in CC. 
Increased phagocytic activity of microglia during demyelination, 
receptors involved in phagocytosis upregulated, especially TREM-2b. 
MHCII increased at peak of demyelination; TNFα; FGF-2, IGF-1 
increased during demyelination 
Role of microglia 
further analyzed 
Analysis in the hippocampus, cortex and cerebellum 
Hoffmann et 
al. 
2008 8 week old 
C57BL/6 male 
mice 
Feeding of 0.2% cuprizone 
for up to 12 weeks followed 
by normal food for 5 weeks 
Cuprizone-treated mice: Startle-induced generalized tonic-clonic 
seizures present (not visible in EEG). During 9 days after 12 weeks 
cuprizone, short but frequent spike discharges recorded (not associated 
with behavioral changes). Marked demyelination (PLP) & degenerated 
neurons (H&E, Fluoro-Jade C) in the hippocampus. Reduced neuron 






2009 8 week & 6 month 
old C57BL/6 male 
mice 
Feeding of 0.2% (young 
mice) or 0.4% (old mice) 
cuprizone for up to 7 weeks 
Characterization of grey & white matter demyelination in hippocampus: 
Grey (hilus of dentate gyrus, stratum lacunosum moleculare) & white 
matter (medial part of the alveus & dorsal hippocampal commissure) 
demyelinated by week 7 (LFB, PLP & CC-1, EM). MBP & PLP mRNA 
expression decreased upon demyelination. Increased number of 
hypertrophic astrocytes in grey matter. Microglia (Iba1) number not 




2009 8 week old 
C57BL/6 male 
mice 
Feeding of 0.2% cuprizone 
for up to 6 weeks 
 
Complete demyelination (PLP, Nogo-A) of the hippocampus until week 
6 (SLM, fimbria not affected); no change in precursor oligodendrocytes 
(NG2); accumulation of microglia (Mac-3) & astrocytes in most regions 
in weeks 3-4.5, declined thereafter. Nestin
+
 cells upregulated upon 
cuprizone, 70% of these cells are GFAP
+
. PSA expression (migration 









Feeding of 0.2% cuprizone 
for up to 6 or 12 weeks 
followed by normal food for 6 
or 12 weeks 
Complete cortical demyelination of C57BL/6 but not BALB/cJ mice after 
6 & 12 weeks of cuprizone; complete remyelination after 6 or 12 weeks 
recovery but delayed remyelination in 12 weeks cuprizone-fed mice. 
Demyelination more severe than in CC; increased number of microglia 
(only in BALB/cJ mice). Increased hypertrophic astrocytes in both 










2009 8 week old 
C57BL/6 male 
mice 
Feeding of 0.2% cuprizone 
up to 5 weeks 
Demyelination (PLP, PLP-mRNA, MBP-mRNA) & reduced number of 
mature oligodendrocytes (CC-1) in the cerebellar marrow incl. the 
lateral cerebellar nucleus, medial cerebellar nucleus, interpositus 
nucleus. Increased number of hypertrophic astrocytes & microglia (Iba1) 
at week 5. Cortical cerebellar white matter not demyelinated but myelin 









8 week old 
C57BL/6 male 
mice 
Feeding of 0.2% cuprizone 
for 12 weeks followed by 
normal food for 8 weeks  
 
Peak of cerebellar grey & white matter demyelination at week 12; 
incomplete remyelination by week 8. Lowest level of oligodendrocytes 
(Nogo-A) at weeks 4 & 12, back to control levels after remyelination. 
Mac-3
+
 cells increased (more prominent in white than grey matter) & 
peaked at week 6 (grey matter) & weeks 8-10 (white matter); peak of 
astrocytes at week 8, declined afterwards. 
Cerebellum 
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Consequences of cuprizone-induced demyelination on a behavioral and cognitive 
level are not studied intensively. So far, impaired motor coordination in a complex 
running wheel, impaired social behavior and sensorimotor function, reduced anxiety 
and impaired spatial working memory are described (Franco-Pons et al, 2007; 
Hibbits et al, 2009; Liebetanz & Merkler, 2006; Makinodan et al, 2009; Xu et al, 
2009). Some of these disturbances are shown to be recovered during remyelination 
(Franco-Pons et al, 2007; Hibbits et al, 2009; Liebetanz & Merkler, 2006; Makinodan 
et al, 2009). Please see Table 3. 
 
The underlying mechanism of the action of cuprizone to induce demyelination is still 
under debate. The initial hypothesis was that a copper deficit in the central nervous 
system leads to disturbed mitochondrial enzyme function, such as for monoamine 
oxidase and cytochrome oxidase (Venturini, 1973). The idea of a copper deficit is 
supported by the finding that cuprizone and the cuprizone-copper complex cross 
neither the intestinal epithelium nor cell membranes and was therefore suggested to 
chelate copper already in the food to induce a copper deficit in mice (Benetti et al, 
2010). A recent study, using proteomic analysis, demonstrated that mitochondrial 
function is the most altered cellular function induced by cuprizone (Werner et al, 
2010), which may result by abnormal concentrations of copper and zinc (Benetti et al, 
2010; Zatta et al, 2005). However, neither a deficit of copper in the brain could be 
shown by others (Zatta et al, 2005), nor did supplementation of copper to the diet 
inhibit the cuprizone-induced toxicity (Carlton, 1966; Carlton, 1967). Therefore, the 
action of cuprizone may involve a more complex mechanism. In vitro studies showed 
that application of cuprizone to primary oligodendrocytes results in metabolic stress 
without cell death unless cuprizone is applied together with inflammatory cytokines, 
suggesting that inflammatory mediators play a role in the cuprizone-induced toxicity 
(Cammer, 1999; Pasquini et al, 2007). So far, several in vivo studies have been 
conducted to investigate underlying mechanisms of cuprizone-induced de- and 
remyelination processes. These studies suggest a role for cytokines such as tumor 
necrosis factor alpha (TNFα), Interferon-gamma (IFN-γ), Interleukin-1ß (IL-1ß) and 
macrophage-inflammatory protein-1 alpha (MIP-1α) (Arnett et al, 2001; Gao et al, 
2000; Iocca et al, 2008; Lin et al, 2006; Mana et al, 2006; Mason et al, 2001b; 
McMahon et al, 2001). Moreover, a role for nitric oxide and growth factors such as 
fibroblast-growth-factor 2 (FGF2) and insulin-like growth factor 1 (IGF-1) is under 
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discussion (Armstrong et al, 2006; Linares et al, 2006; Mason et al, 2001b). Recently 
it was found that type 2 CXC chemokine receptor-positive (CXCR2+) neutrophils from 
the bloodstream are necessary for cuprizone-induced demyelination (Liu et al, 2010). 
These investigators suggest a two-hit process of cuprizone intoxication: First 
mitochondrial functions are disturbed and induce metabolic stress in 
oligodendrocytes and second, peripheral CXCR2+-neutrophils are needed to induce 
demyelination.  
 
To this day, the knowledge about the mechanism of cuprizone-induced demyelination 
has increased, but the process is still not completely understood. Moreover, it is still 
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Table 3: Effect of cuprizone on basic behavioral and cognitive readouts. 
Author Year Species Experimental set-up Results Remarks 
Liebetanz & 
Merkler 
2006 8 week old 
C57BL/6 female 
mice 
Feeding of 0.2% cuprizone 
for 6 weeks followed by 7 
weeks with normal food. 
Motor skill sequence 
(MOSS) test performed in 
weeks 4-6 of demyelination 
and weeks 5-7 of 
remyelination.  
MOSS test performance obtained on a training and complex wheel. 
Training wheel: Significantly lower running distance of cuprizone-fed 
mice over 2 weeks; complex wheel: Influence of all parameters (Vmax, 
Nrun, Dmax, Distac)  worse performance of cuprizone-fed mice vs. 
controls during demyelination.  
Remyelination phase: Comparable performance of cuprizone and 









2007 8 week old 
C57BL/6 male mice 
Feeding of 0.2% cuprizone 
for up to 6 weeks followed 
by normal food for 6 weeks  
Hyperactive behavior in weeks 3-4 (climbing, center-area activity & 
rearing in open field), increased sensorimotor reactivity (freezing as 
response to an auditory click) & motor dysfunction at week 5 (gait 
abnormalities, higher frequency of falling on rota-rod); hyperactivity & 
motor deficits still present in recovery group. 
 
Xu et al. 2009 7-8 week old 
C57BL/6 male mice 
Feeding of 0.2% cuprizone 
for up to 6 weeks 
 
Temporal pattern of higher climbing activity (weeks 2-4), abnormalities 
in sensorimotor function (pre-pulse-inhibition: lower PPI in cuprizone-fed 
mice in weeks 2-3), impaired social behavior (social interaction in pairs: 
reduced in weeks 4-6), lower anxiety levels (EPM: cuprizone-fed mice 
spent more time in open arm & higher open arm entries in weeks 2-6) & 
impaired spatial working memory (Y-maze: lower % of spontaneous 
alternations in weeks 2-6). Reduced enzyme activity (MAO, DBH) at 
week 3 in PFC & hippocampus, higher dopamine levels at week 2, 
lower norepinephrine levels at week 3.  







weeks 2 & 3. 
Hibbits et al. 2009 8-9 week old 
C57BL/6 male mice 
Feeding of 0.2% cuprizone 
either for 6 or 12 weeks; 6 
weeks feeding followed by 
normal food for 6 weeks  
Acute & chronic demyelination: reduced running velocity in the complex 
wheel not recovered by remyelination. Wheel test applicable for 
longitudinal studies. Frequency of interactive behavior of test mice 




2009 Postnatal day 29 or 
57 C57BL/6 female 
mice 
Feeding of 0.2% cuprizone 
from P29-P56 (ED) or P57-
P84 (LD) followed by 
normal food up to day 
P126 
Impaired spatial working memory (Y-maze; lower % of spontaneous 
alternations) directly after cuprizone termination in ED/LD mice & after 
remyelination in ED mice. After remyelination: Reduced distance 
traveled in the center (open field) & disturbed social interaction of ED 
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Many studies still focus on characterization of the cuprizone model to better 
understand the mechanism of de- and remyelination, as well as the involvement of 
the different cell types such as microglia and astrocytes. Moreover, the model has 
been used to develop a new magnetic resonance imaging (MRI) method to predict 
myelin status in vivo (Merkler et al, 2005). As outlined below, the model is 
additionally used for investigations of treatment strategies concerning de- and 
remyelination.  
 
1.2.3 Cuprizone model and treatment strategies 
The cuprizone model serves as a tool to investigate treatment strategies for 
demyelinating diseases such as MS (for an overview see Table 4). Fumaric acid 
esters (FAE) are considered for the treatment of patients with relapsing-remitting MS. 
The corticosteroid methylprednisolone (MP) is an established and commonly used 
drug for MS; both drugs were tested in the cuprizone model. Unfortunately, no effects 
were found in oligodendrocytes, microglia or astrocytes; only minor-effects were 
found on remyelination upon FAE treatment with even a slight delay in remyelination 
by MP treatment (Clarner et al, 2011; Moharregh-Khiabani et al, 2010).  
Minocycline, a second generation tetracycline, reduced the severity of demyelination 
in corpus callosum and cortex. Additionally, microglia and proliferating cells were 
decreased in the cortex, whereas a reduced micoglial number in the corpus callosum 
was observed in just one of the studies. Some contradictory results concerning the 
corpus callosum in these studies could be based on a slightly different treatment 
protocols and different microglia markers used (Pasquini et al, 2007; Skripuletz et al, 
2010a). Improved motor coordination of minocycline treated mice was found using 
the beam walking test (Skripuletz et al, 2010b).  
Sex hormones are suggested to have an effect on disease progression in MS. 
Combined 17β-estradiol/progesterone treatment during cuprizone-induced 
demyelination reduced ventricle enlargement and demyelination and increased the 
number of mature and precursor oligodendrocytes, microglia, astrocytes and 
proliferating cells. The expression of IGF-1 was increased (Acs et al, 2009). No effect 
was found when the mice were treated with only one of the hormones. However, 
another trial using a lower dose of cuprizone and a higher dose of 17β-estradiol 
demonstrated reduced demyelination, increased number of oligodendrocytes and a 
delayed accumulation of microglia. Precursor oligodendrocytes and astrocytes were 
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not affected and IGF-1 and TNFα were decreased, representing different effects of 
combined or single treatment of these hormones (Taylor et al, 2010). Based on the 
geographic distribution of MS, one could assume that nutrients and the climate can 
play a role in the disease mechanism. Supplementation of the cuprizone diet with N-3 
polysaturated fatty acids from salmon reduced the demyelination rate and the 
number of microglia in the corpus callosum. These mice showed an elevated activity 
level and were less anxious (Torkildsen et al, 2009a; Torkildsen et al, 2009b). In 
addition, high dose vitamin D3 was found to be potent in reducing demyelination and 
microglia accumulation after 6 weeks cuprizone feeding; no effects could be detected 
after 2 weeks of recovery (Wergeland et al, 2011).  
Thyroid hormones are necessary for normal axonal myelination. Treatment with 
triiodothyronine (T3) after chronic demyelination resulted in gradually improved 
myelination, increased numbers of mature/precursor oligodendrocytes and 
proliferating cells upon recovery (Harsan et al, 2008). 
Growth factors are shown to promote oligodendrocyte precursor proliferation, survival 
and/or differentiation. A growth factor mix of PDGF-AA, neurotrophin-3, basic FGF-1 
and IGF-1 was applied into the lateral ventricle 3 weeks after cuprizone feeding, 
which was followed by improved remyelination, activation of oligodendrocyte 
precursor proliferation and maturation (Kumar et al, 2007). 
 
Based on the behavioral changes observed during cuprizone feeding and 
accumulating findings of white matter abnormalities in schizophrenia (Kubicki et al, 
2005; Lim et al, 1999; Mitelman et al, 2007; Uranova et al, 2011), the cuprizone 
model was suggested to serve as an animal model to study this disease (Yang et al, 
2009). Quetiapine, clozapine and olanzapine (second generation antipsychotics) and 
haloperidol (a first generation antipsychotic) were tested in the cuprizone model. 
When these drugs were given during the recovery phase, there was no effect on the 
status of myelin but rather enhanced performance in working memory (Xu et al, 
2011). Administration of the antipsychotics during cuprizone feeding increased the 
degree of myelination (Chandran et al, 2011; Xiao et al, 2008; Xu et al, 2010; Zhang 
et al, 2008) and the number of mature oligodendrocytes was elevated, whereas the 
number of microglia and astrocytes were decreased within the corpus callosum 
(Zhang et al, 2008). Quetiapine and clozapine improved spatial working memory and 
social interaction in the cuprizone-fed mice (Xiao et al, 2008; Xu et al, 2010). 
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Haloperidol itself already influenced the performance in some of the behavior tests in 
healthy mice, which made it difficult to draw strong conclusions from these 
experiments. The results of these studies are presented in Table 5. 
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Table 4: The cuprizone model and treatment trials related to multiple sclerosis. Antibodies and/or methods used are given in brackets. 




2010 8 week old 
C57BL/6 
male mice 
Feeding of 0.2% cuprizone for 5 weeks 
combined with oral treatment of 
monomethylfumarate or dimethylfumaric 
acid (15mg/kg) twice daily followed by 
normal food for 1 week. 
Only a minor effect of monomethylfumarate on remyelination in the CC 
but not cortex in weeks 5-6 (LFB, PLP, MOG, MBP). No effects on 






Feeding of 0.2% cuprizone for 5 weeks 
followed by normal food for 9 or 21 days 
combined with daily injections (i.p.) of 
methylprednisolone (15mg/kg). 
Early (day 9) and late (day 21) during recovery, methylprednisolone 
treatment reduced myelination index (PLP) compared to placebo-treated 
mice. Mature oligodendrocytes (APC), microglia (Iba1) & astrocytes not 
influenced. 
 
Acs et al. 2009 8 week old 
C57BL/6 
male mice 
Feeding of 0.2% cuprizone for 5 weeks 
combined with s.c. depot injections of 
progesterone (25µg), 17β-estradiol 
(50ng) or a mixture of both twice weekly. 
No effect of progesterone & 17β-estradiol alone.  
Both hormones together: Reduced ventricle enlargement (MRI) and 
demyelination in CC (LFB, mRNA: MBP, PLP), increased number of 
mature/precursor oligodendrocytes (APC/PDGFRα), microglia (Iba1), 
proliferating cells (Ki67) & the mRNA expression of GFAP (astrocytes). 
IGF-1 expression also increased. 
 
Taylor et al. 2010 8 week old 
C57BL/6 
male mice 
Feeding of 0.125% cuprizone up to 6 
weeks followed by normal food for 1 
week. 17β-estradiol (0.42mg/day) 
pellets were implanted s.c. 5 days prior 
cuprizone feeding. 
Demyelination in CC (LFB) less severe & higher number of mature 
oligodendrocytes (GST-pi) at weeks 3 & 5 of demyelination. No effect on 
precursor oligodendrocytes & astrocytes; delayed microglia 
accumulation (RCA-1); reduction of TNFα & IGF-1 expression at weeks 




2007 8 week old 
C57BL/6 
male mice 
Feeding of 0.2% cuprizone for 5 weeks. 
Feeding was combined in the 2
nd
 week 
with injections (i.p.) of minocycline (50 
mg/kg twice daily at days 1-2; daily at 
days 3-7 & 25 mg/kg daily until the end 
of experiment). 
Demyelination (LFB, MBP) in CC less pronounced after 5 weeks 







8 week old 
C57BL/6 
male mice 
Feeding of 0.2% cuprizone for 6 weeks 
combined with injections (i.p.) of 
minocycline (50 mg/kg twice daily at 
days 1-2; daily at days 3-7 & 25 mg/kg 
daily until the end of experiment). 
Less severe demyelination by minocycline treatment in the cortex in 
weeks 5-6 & in the CC in weeks 4-5 (PLP,MBP,CNPase). No effect on 
myelin re-expression; no effect on mature (Nogo-A) or precursor (NG2) 
oligodendrocytes & astrocytes in cortex & CC; decreased microglia 
number (Mac-3, RCA-1) & proliferation (Ki67) at week 5 in cortex but not 
CC. Improved motor coordination (beam walking) in weeks 5-6. 
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Feeding of mice with the same food but 
supplemented with different lipid 
sources (salmon, cod liver, soybean & 
olive oils). At 8 weeks of age 0.2% 
cuprizone was added to the food for 6 
weeks followed by 1 week without 
cuprizone. 
Salmon/cuprizone group: Reduced volume of hyperintense brain lesions 
measured in T2-weighted MRI images (correlated with increased water 
content in brain parenchyma) at cuprizone week 5; demyelination (LFB, 
PLP) of the CC less severe at week 6 & after 1 week recovery. Lowest 
number of microglia in CC at week 6 but no group differences after 
recovery. Soybean oil/cuprizone group: Tendency to improve 










Feeding of mice with the same food but 
supplemented with different lipid 
sources (salmon, cod liver, soybean & 
olive oils). At 8 weeks of age 0.2% 
cuprizone was added to the food for 6 
weeks. 
Salmon/cuprizone group: Confirmed their previous finding of reduced 
demyelination. New: Less body weight loss and increased activity levels 
in the EPM, visits of open and closed arm increased without a 








Feeding with food containing <50 IU/kg, 
500 IU/kg, 6200 IU/kg or 12500 IU/kg 
vitamin D3. After 2 weeks, diets were 
supplemented with 0.2% cuprizone for 6 
weeks followed by 2 weeks without 
cuprizone. 
Serum levels of vitamin D3 increased or deceased according to the 
feeding. High dose of vitamin D3: Decreased demyelination in the CC, no 
influence on remyelination (LFB, PLP); depletion of mature 
oligodendrocytes (Nogo-A) not influenced; reduced microglia 
accumulation (Mac-3) in CC. 2 weeks after recovery microglia further 








Feeding of 0.2% cuprizone for 12 weeks 
followed by normal food for 12 weeks +/- 
triiodothyronine hormone (T3; 0.3µg/g 
body weight) daily for 3 weeks (i.p.). 
Hyperthyroidism 3 weeks after treatment started but transient at week 6.  
T3-effects: DTI: Fractional anisotropy back to normal levels at week 12 in 
all ROIs (e.g. genu, splenium & cerebellum); radial diffusivity gradually 
decreased, reached normal levels until week 3 (cerebellum), 6 
(splenium) or 12 (genu). Gradual increase of carbonic anhydrase II
+
- 
oligodendrocytes & MBP in the CC/cerebellum (weeks 3-12 of recovery) 






& proliferating cells from week 3 
on, gradual decrease of CD45
+
 microglia & increase of myelinated 
axons. 
 






Feeding of 0.2% cuprizone for 3 weeks 
followed by normal food + a single 
injection of a growth factor mix (PDGF-
AA, NT3, bFGF,IGF-1) into the lateral 
ventricle. 
2-5 days post injection (dpi): Increased cell proliferation & migration in 
CC, rostral migratory stream, cortex & striatum in wild-type & cuprizone-









 cells partially differentiated into mature oligodendrocytes 
(GST-pi). More myelinated fibers & thicker myelin sheaths in growth 
factor-treated cuprizone mice 21 dpi. Increased apoptosis in wild-type 
and cuprizone mice upon growth factor treatment. 
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Table 5: The cuprizone model and treatment trials related to schizophrenia. Antibodies and/or methods used are given in brackets. 
Author Year Species Experimental set-up Results Remarks 
Xiao et al. 2008 8 week old 
C57BL/6 
male mice 
Feeding of normal chow for 1 week 
followed by feeding with 0.2% cuprizone 
for 4 weeks. Quetiapine (10mg/kg/day) 
via drinking water over all 5 weeks. 
Prevention of myelin breakdown (MBP) in whole brain (especially cortex) 
and improvement of spatial working memory (Y-maze: spontaneous 
alternation, arm entries). 
 
Zhang et al. 2008 8 week old 
C57BL/6 
mice 
Treatment with quetiapine 
(10mg/kg/day) for 6 weeks via drinking 
water; feeding of 0.2% cuprizone started 
after 1
st
 week of quetiapine treatment for 
5 weeks. 
Elevated degree of myelination (LFB,MBP IHC&WB) quantified in whole 
brain & GST-pi
+
 oligodendrocytes in CC by quetiapine. Decreased 
activity of superoxide dismutase 1 in the cortex of cuprizone mice and 
back to normal levels upon quetiapine treatment. Decreased number of 
CD11b
+
 microglia & GFAP
+
 astrocytes in CC. 
 




Feeding of 0.2% cuprizone for 14-42 
days combined with daily  injections 
(i.p.) of haloperidol (1mg/kg), clozapine 
or quetiapine (10mg/kg). 
All antipsychotics blocked cuprizone-induced PPI deficit & reduced 
cuprizone-induced levels of dopamine & norepinephrine in PFC (day14). 
Clozapine & quetiapine counteracted cuprizone-induced decrease in 
spontaneous alternation in Y-maze & impaired social interaction (day28). 
Clozapine & haloperidol increased myelination in PFC; clozapine & 








Xu et al. 2011 6 week old 
C57BL/6 
male mice 
Feeding of 0.2% cuprizone for 5 weeks 
followed by normal food for 3 weeks 
combined with daily injections (i.p.) of 
clozapine or quetiapine (10mg/kg), 
haloperidol (1mg/kg) or olanzapine 
(3mg/kg). 
Cuprizone feeding influenced the performance in EPM (increased time in 
open arm), reduced social interaction & spatial working memory of mice. 
Fast spontaneous recovery within 14-21 days concerning EPM but 
social interaction & spatial working memory still reduced. Only clozapine, 
quetiapine & olanzapine promoted the recovery of spatial working 














Feeding of normal chow for 1 week 
followed by 0.2% cuprizone for 5 weeks. 
Quetiapine (10mg/kg) was administered 
via drinking water during the 6 weeks. 
T2-weighted MRI images: Significant decrease in the signal intensity 
ratio counteracted by quetiapine. DTI: fractional anisotropy levels back 
to control levels under quetiapine treatment. Optical density of LFB & 
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1.3 Erythropoietin 
1.3.1 Properties and pathways 
EPO is a hematopoietic growth factor regulating the survival, proliferation and 
differentiation of erythroid progenitor cells (Jelkmann, 1992; Klingmuller, 1997). In 
1977, the human EPO molecule was purified from urine, opening the possibility for its 
characterization (Miyake et al, 1977). EPO is a 30.4 kDa glycoprotein which belongs 
to the class I cytokine superfamily and is mainly expressed in the fetal liver and adult 
kidney (Dame et al, 1998; Fried, 1972; Koury et al, 1988; Zanjani et al, 1977). 
Additionally, EPO is identified to be expressed in the brain (Bernaudin et al, 1999; 
Marti, 2004; Marti et al, 1996; Masuda et al, 1994). The expression of EPO and the 
EPO receptor (EPOR) peaks during mid-gestation, whereas both are expressed in 
low levels during adulthood (Juul et al, 1998; Liu et al, 1994; Siren et al, 2001). 
However, in both the hematopoietic system and in the brain, EPO expression is 
upregulated under hypoxic conditions (Brines & Cerami, 2005; Jelkmann, 2007; 
Noguchi et al, 2007; Sasaki et al, 2001; Siren & Ehrenreich, 2001). The importance 
of the EPO-EPOR system during normal brain development was shown in EPO and 
EPOR null mice. The lack of erythropoiesis led to death of mice at day E13.5. Brain 
development was already impaired at day E10.5 (Yu et al, 2002). Mice with a 
conditional knockout of the brain EPOR survived through adulthood but showed 
reduced neurogenesis (Tsai et al, 2006). 
 
The EPOR is a cell surface receptor and belongs to the cytokine class I receptor 
superfamily (Klingmuller, 1997; Youssoufian et al, 1993). These receptors are 
characterized by a single hydrophobic transmembrane domain, an extracellular N-
terminal domain with conserved cysteines and a WSXWS-motif and a cytosolic 
domain that lacks intrinsic kinase activity (Jelkmann, 2007). The cytoplasmic domain 
of the EPOR is associated with the Janus kinase 2 (Jak2). Binding of EPO to the pre-
formed EPOR homodimer activates Jak2, which phosphorylates 8 tyrosines located 
in the cytoplasmic domain of EPOR. These serve as docking sites for downstream 
molecules, which can become phosphorylated and activate several intracellular 
pathways (Jelkmann, 2007). Signaling pathways involved are signal transducers and 
activators of transcription (Stat), phosphatidylinositol 3-kinase (PI3K) and ras-
mitogen-activated protein kinase (Ras-MAPK) (Brines & Cerami, 2005; Siren & 
Ehrenreich, 2001).  
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For more than 20 years, EPO has been used to treat patients suffering from anemia 
and is therefore accepted as a well tolerated and safe therapy (Jelkmann, 1992). 
Some of the first observations of neuroprotective properties of EPO were the 
prevention of glutamate-induced neuronal cell death in vitro (Morishita et al, 1997), 
anti-apoptotic and neurotrophic effects of EPO after unilateral fimbria-fornix 
transection (Konishi et al, 1993) and reduced ischemia-induced neuronal damage 
(Sakanaka et al, 1998) in rodents. Ever since, several studies could demonstrate 
neuroprotective and neuroregenerative properties of EPO in preclinical and clinical 
studies ranging from cerebrovascular diseases and neuroinflammatory diseases to 
neurodegeneration (for an extensive review please see (Sargin et al, 2010)). In these 
studies, EPO has been shown to be anti-apoptotic, anti-oxidative, anti-inflammatory, 
neurotrophic, angiogenetic and stimulate stem cell differentiation (Bartels et al, 2008; 
Brines & Cerami, 2005; Byts & Siren, 2009; Chen et al, 2007; Shingo et al, 2001; 
Siren & Ehrenreich, 2001). To emphasize that these effects are independent of the 
hematopoietic action of EPO, it was important to investigate whether EPO is able to 
cross the BBB. Indeed, it has been shown that a small proportion of high doses of 
exogenous EPO is able to cross the BBB using biotinylated-EPO in rodents (Brines 
et al, 2000) and indium-labeled EPO in healthy subjects and schizophrenic patients 
(Ehrenreich et al, 2004). The exact mechanism of how EPO crosses the BBB is not 
yet known. Additionally, it is still questionable if the EPOR responsible for the 
neuroprotective effect of EPO in the brain is the same as for the hematopoietic 
system. Brines and colleagues suggested a heteromeric receptor complex consisting 
of one EPOR subunit and one ß-common receptor subunit which belongs to the 
interleukin-3 receptor family (Brines et al, 2004). Moreover, the identification of an 
EPO analogue with potent neuroprotective but no hematopoietic action is of major 
interest for clinical applications.  
 
1.3.2 Erythropoietin and oligodendrocytes 
Oligodendrocytes are the myelinating cells in the CNS. They allow fast saltatory 
conduction of signals along the axons and more recent investigations show a 
supportive function of oligodendrocytes for axon survival (Nave, 2010).  
The expression of EPO and EPOR has been found in vitro in astrocytes, neurons, 
microglia and oligodendrocytes (Masuda et al, 1994; Morishita et al, 1997; Nagai et 
al, 2001; Sugawa et al, 2002). The effect of EPO on oligodendrocytes is not 
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extensively studied yet. The first who clearly showed the presence of EPO and 
EPOR mRNA expression in cultured rat oligodendrocytes were Sugawa and 
colleagues (Sugawa et al, 2002). Moreover, they claimed that EPO promotes 
differentiation/maturation of oligodendrocytes as shown by direct EPO treatment and 
by a co-culture experiment with astrocytes. In this study, the involvement of the 
classical EPO pathway Jak2/Stat5 could not be detected. In several different disease 
models, EPO has been found to preserve myelin sheaths (Gorio et al, 2002; Iwai et 
al, 2010; Kumral et al, 2007; Li et al, 2004; Liu et al, 2011; Vitellaro-Zuccarello et al, 
2007; Yamada et al, 2011) and resulted in earlier and faster white matter 
reorganization after ischemia shown by MRI (Li et al, 2009). Direct preservation of 
oligodendrocytes was observed in a model of neurotrauma (Sargin et al, 2009). A 
very consistent finding so far is that EPO enhances proliferation of precursor 
oligodendrocytes and increases the maturation of oligodendrocytes, and is therefore 
suggested to enhance oligodendrogenesis (Iwai et al, 2010; Vitellaro-Zuccarello et al, 
2007; Zhang et al, 2005; Zhang et al, 2010). In models for periventricular 
leukomalacia and traumatic spinal cord injury, it was shown that EPO reduced the 
apoptosis rate in the white matter (Arishima et al, 2006; Gorio et al, 2002; Kumral et 
al, 2007). In vitro, EPO decreased the cytotoxicity in oligodendrocyte cultures after 
interferon-γ and lipopolysaccharide or hydrogen peroxide administration (Genc et al, 
2006; Mizuno et al, 2008). Furthermore, anti-inflammatory potential of EPO was 
shown by a decrease in nitrite production and reduced mRNA expression of inducible 
nitric oxide synthase in mature oligodendrocyte cultures, as well as by a reduction of 
cytokine levels in the developing rat brain (Genc et al, 2006; Kumral et al, 2007). 
Some discrepancies between studies may result from different study designs or 
different protocols of EPO application. Further studies are needed to clarify the effect 
of EPO on oligodendrocytes and myelin. In addition, this is of special interest 
concerning alternative treatment strategies for demyelinating diseases such as MS.  
 
1.4 Scope of the thesis 
 
As outlined above, EPO has been proven to bear neuroprotective and 
neuroregenerative properties shown in several disease models. With respect to 
oligodendrocytes, EPO is suggested to mainly promote oligodendrogenesis and 
preserve myelin under different pathological conditions. It is of major interest to 
understand the effect of EPO on oligodendrocytes in more detail concerning 
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alternative treatment strategies for demyelinating diseases such as MS. In the most 
commonly used animal model for MS, experimental autoimmune encephalomyelitis 
(EAE), EPO has been shown to delay the disease onset, has immune-modulatory 
capacity by reducing inflammatory cytokine production and improves 
electrophysiological and histological readouts of EAE ((Agnello et al, 2002; Brines et 
al, 2000; Chen et al, 2010; Diem et al, 2005; Kang et al, 2009; Leist et al, 2004; Li et 
al, 2004; Sattler et al, 2004; Savino et al, 2006; Thorne et al, 2009; Yuan et al, 2008; 
Zhang et al, 2005) and reviewed in (Bartels et al, 2008; Sargin et al, 2010)). The 
effect of EPO on demyelination in the EAE model is rarely investigated - so far it has 
been shown that EPO reduces demyelination and enhances proliferation of precursor 
oligodendrocytes in the central nervous system but not in the optic nerve (Dasgupta 
et al, 2011; Diem et al, 2005; Li et al, 2004; Sattler et al, 2004; Zhang et al, 2005). 
The aim of this thesis was to make use of the cuprizone mouse model to investigate 
the effect of EPO on demyelination and remyelination processes without direct 
influence of immune-inflammatory components. This was studied with different 
experimental designs:  
 
1. Effect of EPO on remyelination 
In this experimental set-up, the effect of EPO was investigated after a single and 
repeated exposure to cuprizone. The idea of repeated cuprizone intoxication was to 
apply an additional “demyelination-hit” after a partial recovery. This is related to 
disease conditions such as in the relapsing-remitting disease course in MS. EPO 
application started in the beginning of the recovery phase and therefore allowed 
investigation of the effect of EPO on the remyelination process. 
 
2. Effect of EPO on demyelination 
The experimental design included a single cuprizone exposure followed by a 
recovery phase. From weeks 4-6 of cuprizone feeding, EPO was applied to 
investigate the effect on demyelination.  
 
The analyses of the experiments included behavioral tests, MRI, 
immunohistochemical staining, western blot analysis and quantitative RT-PCR. It was 
hypothesized that EPO improves cuprizone-induced changes in these readouts. So 
far, no study exists to investigate the effect of EPO in the cuprizone mouse model. 
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2 MATERIALS AND METHODS 
2.1 Animals 
 
All experiments were approved by and conducted in accordance with the regulations 
of the local Animal Care and Use Committee (Niedersächsisches Landesamt für 
Verbraucherschutz und Lebensmittelsicherheit; AZ 33.11.42502-04-040/08 and AZ 
33.9-42502-04-10/0157). 4 week old C57BL/6 male mice were purchased from 
Charles River Laboratories (Sulzfeld, Germany) for all experiments. They were 
housed in groups of 5 in standard plastic cages and maintained in a temperature-
controlled environment (212°C) on a 12 hour light/dark cycle with food (Sniff, Soest, 
Germany) and water available ad libitum. 8 week old C57BL/6 male mice were used 
in each experiment if not indicated otherwise. Body weight of mice was monitored 
over the whole experimental time. Moreover mice were carefully observed to see any 
adverse effects of the treatment. 
 
2.2 Preparation of cuprizone containing food 
2.2.1 Food pellets containing 0.2% cuprizone  
Food pellets containing 0.2% cuprizone (weight/weight) (Sigma Aldrich, Taufkirchen, 
Germany) were customer made by Sniff (Soest, Germany).  
 
2.2.2 Standard ground chow containing 0.2% or 0.3% cuprizone 
A plastic container was used to carefully mix standard ground chow (Sniff, Soest, 
Germany) with cuprizone. Food was freshly prepared daily. Mice in the control 
groups were fed with the regular standard ground chow without cuprizone added. 
 
2.3 Erythropoietin administration 
 
Erythropoietin (NeoRecomon; 50000 IU/ml; Roche, Penzberg, Germany) was freshly 
prepared by dilution with EPREX solvent solution (Pharmacy at the University 
hospital, Göttingen, Germany). Mice received a dose of 5000 IU/kg body weight 













Normal food / no treatment
Cuprizone feeding (0.2%)
Cuprizone feeding (0.3%)
2.4 Measurement of the haematocrit 
 
To measure the haematocrit, blood was taken from the heart and collected in EDTA-
coated-tubes (Sarstedt, Nümbrecht, Germany). The blood was taken up by micro-
haematocrit capillaries that were sealed with a kit (Brand, Wertheim, Germany). The 
tubes were centrifuged for 10 minutes; 8000 rpm (Heraeus Biofuge haemo; Kendro; 
Osterode; Germany). The haematocrit was directly measured on a micro-haematocrit 
scale (Kendro, Osterode, Germany).  
 
2.5 Experimental design  
2.5.1 Pilot experiments 
In the first pilot experiment, mice were divided into two groups (44 mice/group); one 
group received normal food pellets and the other food pellets containing 0.2% 
cuprizone over a period of 7 weeks (Figure 2). Body weight and motor performance 





                        
                    Figure 2: Experimental scheme of first pilot experiment. N=44/group 
 
In the second pilot experiment, the difference of cuprizone administration via food 
pellets and rodent ground chow was tested. Over a period of 19 days, 7 week old 
mice (N=3) were exposed to 0.2% or 0.3% cuprizone mixed in rodent ground chow 
(Figure 3) and 6 week old mice (N=3) received food pellets containing 0.2% 






                        Figure 3: Experimental scheme of second pilot experiment. 
                    Mice (N=3) received cuprizone mixed into ground chow. 
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                         Figure 4: Experimental scheme of second pilot experiment. 




2.5.2 Investigation of EPO on remyelination 
2.5.2.1 Single treatment of cuprizone 
To investigate the effect of EPO on remyelination after an acute demyelination 
phase, a 4-arm design was used (N=20/group). Two groups served as control groups 
and received normal ground chow; the other two were fed with 0.2% cuprizone mixed 
into ground chow. After 6 weeks all mice were put on normal chow and one control 
and one cuprizone group received either placebo or EPO every other day over the 
next 3 weeks (Figure 5). Mice were sacrificed and used for protein analysis. During 

















Figure 5: Experimental scheme of the single treatment group to 
investigate the effect of EPO on remyelination. N=20/group; 
i.p.=intra-peritoneal; bw=body weight; EPO=erythropoietin. 
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Placebo injections (PL)
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Sacrifice of mice
2.5.2.2 Repeated treatment of cuprizone 
To investigate the effect of EPO on remyelination after a repeated exposure to 
cuprizone, a 4-arm design was used (N=25/group). Two groups served as control 
groups and received normal ground chow; the other two were fed with 0.2% 
cuprizone mixed into ground chow. After 6 weeks all mice were put on normal chow 
and one control and one cuprizone group received either placebo or EPO every other 
day over the next 3 weeks. This was followed by a second cycle of cuprizone feeding 
over 6 weeks and a second recovery phase for 3 weeks with placebo/EPO injections 
as described before (Figure 6). After the second demyelination phase (week 15) and 
at the end of the experiment (week 18) mice were tested on the beam balance test 
(see 2.6.2). Rota-rod was performed twice weekly during the whole experiment (see 
2.6.1). At the end of the experiment (week 18) mice were used for MRI and the 
measurement of acoustic evoked potentials (AEPs) and sacrificed afterwards. Brain 








Figure 6: Experimental scheme of the repeated treatment group to investigate the effect of EPO on 
remyelination. N=25/group; i.p.=intra-peritoneal; bw=body weight; EPO=erythropoietin. 
 
2.5.3 Investigation of EPO on demyelination 
To investigate the effect of EPO on demyelination during an acute demyelination 
phase, a 4-arm design was used (N=26/group). Two groups received normal ground 
chow and the other two were exposed to 0.2% cuprizone over 6 weeks. From weeks 
4 to 6 of this period, mice were injected intra-peritoneal (i.p.) with EPO or placebo 
(Figure 7). After 6 weeks, 8-11 mice/group were used for MRI and 
immunohistochemistry; whereas 15 mice/group received normal chow over the next 
3 weeks. At week 9, mice were used for MRI and scarified afterwards. Additionally, at 
weeks 6 and 9 the beam balance test and rota-rod was performed (see 2.6).   
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All tests and analyses were performed in a ‘blinded’ fashion. The experimenter was 
not aware of any group assignment until the end of the experiments. 
 
 
2.6 Behavioral testing  
 




Rota-rod is a test for motor function, balance and coordination and comprises a 
rotating drum which is either at constant speed or accelerated from a lower to higher 
speed over a distinct time period. The protocols used are described before (Carter et 
al, 2001) and were modified in our laboratory (e.g. (Radyushkin et al, 2010)). Two 
protocols were used in these studies, first rota-rod with a constant speed of 16 
resolutions per minute (rpm) and second an accelerated rota-rod of 4-40 rpm. Both 
protocols started with a habituation day which involved placing each mouse 
individually on the non-rotating drum for 5 minutes. The actual experiment started on 
the second day of testing.  
 
 
Figure 7: Experimental scheme to study the effect of EPO on 
demyelination. N= 26/group; i.p.=intra-peritoneal;  bw=body weight; 
EPO=erythropoietin. 
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2.6.1.1 Constant rota-rod 
In the first pilot experiment, mice were tested twice every week throughout the whole 
experimental time. The rota-rod (Ugo Basile, Comerio, Varese, Italy) was set to a 
constant speed of 16 rpm and the time mice were able to stay on the rod (falling 
latency) was measured. Each mouse had 3 trials per day with an inter-trial interval of 
5 minutes. A cut-off time was set to 5 minutes. After each trial, the rotating drum was 
cleaned. From week 5 on, all mice were switched to an accelerated rota-rod.  
 
2.6.1.2 Accelerated rota-rod 
In all experiments (except the first part of the first pilot experiment) an accelerated 
rota-rod protocol was used. The speed increased from 4-40 rpm within 5 minutes. 
Mice were placed on the rotating drum and the falling latency was recorded. For the 
second part of the first pilot experiment and for the experiment to investigate the 
effect of EPO on remyelination, all mice were tested twice every week with one trial 
per day over the whole experimental period.  
In order for the experiment to investigate the effect of EPO on demyelination, the 
mice were first tested at baseline before cuprizone exposure. On the first day after 
the habituation, the mice were tested on the accelerated rota-rod (1 trial per day).  To 
assess motor learning, the test was repeated 24 hours later. At both, week 6 and 9, 
the accelerated rota-rod was performed on 3 consecutive days.  
 
2.6.2 Beam balance 
Beam balance is a test for motor coordination and vestibulomotor function. The set-
up consists of an elevated beam that has an enclosed escape platform including 
bedding on one end. The mice are trained to cross the beam towards the enclosed 
escape platform and the latency of mice to cross the beam is recorded (Carter et al, 
2001). The protocol used in these studies are based on the common beam walking 
protocol but was further modified. All the beams were 59 cm long and varied in their 
diameter. The light in the experimental room was dimmed and the start side of the 
beam was illuminated. For habituation, a 25 mm diameter beam was used. On the 
first day of habituation, the mice were placed right in front of the enclosed escape 
platform; when the mouse entered the box they were allowed to stay there for 30 
seconds (s). After a 5 minute inter-trial interval, mice were placed in the middle of the 
beam and the mice had to walk to and enter the escape box. The mouse was again 
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left there for 30 s. On the second day, habituation was performed by first placing the 
mouse in the middle of the beam followed by a 5 minute inter-trial interval and then 
starting again by placing the mouse at the start of the beam. The mouse then had to 
walk again to the escape box and stayed there for 30 s. After the habituation, the 
actual test was performed. The beam was exchanged to a 10 mm diameter beam, 
the mouse was placed at the start of the beam and the latency to reach the escape 
box was measured. On the third day the mice were tested on the 8 mm diameter 
beam and the latency to cross the beam was again recorded. If a mouse failed to 
stay on the beam, the test was repeated, maximum were 3 trials/mouse. If all trials 
failed, a cut-off time of 60 s was set for the analysis of data. This protocol including 
an intensive habituation phase was used at week 15 and at baseline to investigate 
the effect of EPO on remyelination and on demyelination respectively. At all other 
time points the beam balance test was performed on 2 consecutive days; on the first 
day a short habituation was applied by placing the mice again in the middle and start 
of the 25 mm beam. This was followed by testing the mice on the 10 mm beam. On 
the second day the latency to walk across the 8 mm beam was recorded. The same 
criteria for non-performer were used as described above. The performance of mice 
was calculated by the duration on the beam in % of control.  
 
2.7 Assessment of hearing  
2.7.1 Startle response of mice 
To control for hearing of mice, a test using the startle response of mice as a 
response to acoustic stimuli can be used (Logue et al, 1997). 
 
Each mouse was placed in a small metal cage (90x40x40 mm) to restrict major 
movements and exploratory behavior. The cages were equipped with a movable 
platform floor attached to a sensor that records vertical movements of the floor. The 
cages were placed in four sound-attenuating isolation cabinets (TSE GmbH, Bad 
Homburg, Germany). Startle reflexes were evoked by acoustic stimuli delivered from 
a loudspeaker that was suspended above the cage and connected to an acoustic 
generator. The startle reaction to an acoustic stimulus evokes a movement of the 
platform and a transient force results from this movement of the platform. This was 
recorded with a computer during a recording window of 100 ms and stored for further 
analysis. The recording window was defined from the onset of the acoustic stimulus. 
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An experimental session consisted of a 2 minutes habituation to 65 dB background 
white noise (continuous throughout the session), followed by a baseline recording for 
1 minute at background noise. After baseline recording, stimuli of different intensity 
and fixed 40 ms duration were presented. Stimulus intensity was varied between 65 
dB and 120 dB, such that 19 intensities from this range were used with 3 dB steps. 
Stimuli of each intensity were presented 10 times in a pseudorandom order with an 
interval ranging from 8 to 22 s. The amplitude of the startle response (expressed in 
arbitrary units; AU) was defined as the difference between the maximum force 
detected during a recording window and the force measured immediately before the 
stimulus onset. Amplitudes of responses for each stimulus intensity were averaged 
for individual animals. Mean values for each experimental group were used for 
analysis of the stimulus-response curves. 
 
2.7.2 Recording of auditory brain stem responses (ABRs) 
This measurement was done in collaboration with Nicola Strenzke, Department of 
Otorhynolaryngology, University hospital, Göttingen, Germany. 
 
Animals were anaesthetized intra-peritoneally with a combination of ketamine (125 
mg kg-1) and xylazine (2.5 mg kg-1) and the heart rate was constantly monitored to 
control the depth of anesthesia. The core temperature was maintained constant at 
37°C using a rectal temperature-controlled heat blanket (Hugo Sachs Elektronik – 
Harvard Apparatus GmbH, March-Hugstetten, Germany). For stimulus generation, 
presentation, and data acquisition, the TDT III Systems was used (Tucker-Davis-
Technologies, Ft Lauderdale, FL), run by custom-written Matlab software (The 
Mathworks). Clicks of 0.03 ms duration were calibrated using a ¼‟‟ Brüel and Kjaer 
microphone (D 4039, Brüel & Kjaer GmbH, Bremen, Germany) and were presented 
at 20 and 90 Hertz in the free field ipsilaterally using a JBL 2402 speaker (JBL GmbH 
& Co., Neuhofen, Germany). The potential difference between vertex and mastoid 
subdermal needles was amplified 20 times and sampled at a rate of 50 kilohertz for 
20 ms, 2x2000 times to obtain two mean ABRs for each sound intensity. Hearing 
threshold was determined with 10 dB precision as the lowest stimulus intensity that 
evoked a reproducible response waveform in both traces by visual inspection. 
Amplitudes and latencies of ABR waves I-V (Jewett & Williston, 1971) were analyzed 
using a semi-automatic custom-written Matlab routine. 
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2.8 MRI analysis 
 
All MRI measurements and the analysis of the %MTR were performed in 
collaboration with Susann Boretius, Max Planck institute for biophysical chemistry, 
Göttingen, Germany. Volumetrical analysis of the data obtained was done by myself. 
 
2.8.1 MRI measurements 
6 mice per group underwent MRI at the time points described above. The animals 
were anesthetized with 1-1.5% isoflurane in a mixture of oxygen and ambient air and 
positive ventilated via endotracheal tube. The artificial respiration was controlled, by 
a homemade sensor placed on the chest of the mice. During the measurements the 
mice were fixed at the head and the body temperature (36±1°C) was kept constant 
by a rectal temperature-controlled heat blanket. 3D Fast Low-Angle Shot (FLASH) 
MRI (TR/TE = 14.9/3.9 ms, 45 minutes each) was performed at 9.4 T (Bruker 
Biospin, Ettlingen, Germany) with 110 µm isotropic spatial resolution using a 4-
element phased-array surface coil (Bruker Biospin, Ettlingen, Germany) for signal 
reception. 3 data sets were obtained: a T-1 weighted data set with a flip angle of 12° 
and 2 proton-density (PD) weighted data sets with a flip angle of 5°. In addition, 
magnetization transfer (MT) weighted images were obtained by off-resonance 
irradiation (frequency offset 3 kilohertz, Gaussian pulse, duration 3.5 ms, flip angle 
135°). The MT weighted data set together with the PD weighted image was used to 
calculate the magnetization transfer ratio (MTR) in percentage. %MTR=((PD-
MT)/PD)x100%. To reduce the background noise the images were modified by a mild 
Gauß filter (s=1 Pixel, 3x3 Kernel) before. T1 maps were calculated by the T1- and 
PD-weighted data sets. In addition, multi-slice T2-weighted images were acquired 
with use of a fast spin-echo MRI sequence (TR/TE=5300/64 ms, 8 echoes, 26 
sections) at an in-plane resolution of 80 µm and a section thickness of 300 µm 
(Boretius et al, 2009). 
 
2.8.2 Volumetrical analysis 
The brain volume (total brain, brain matter, hippocampi, ventricles) was determined 
by using Amira software (Visage Imaging GmbH, Berlin, Germany). In the T1 maps 
every second slice in the transversal layer was analyzed. The different regions were 
manually surrounded and labeled by going through the brain from superior to inferior. 
The coronal and sagittal layer was always consulted to reliably label the different 
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regions. The data obtained by Amira were non-dimensional and only represented the 
number of pixel within the regions. One pixel had a volume of 110*110*110 µm, 
therefore the data were multiplied by this volume and by 2 (because only every 
second brain slice was analyzed).  
 
2.8.3 %MTR 
%MTR was calculated pixel by pixel resulting in a 3-dimensional parameter map. 
From this MTR-map the corpus callosum as region of interest (ROI) was selected on 
a sagittal oriented slice, 4 slices away from the center. The corpus callosum was 
divided in 3 parts, rostral, central, and caudal allowing to separate between different 
regions within the corpus callosum.  
 
 
2.9 Staining of mouse brains 
2.9.1 Preparation of tissue 
Animals were anesthetized with 0.25% tribromoethanol (Avertin; 0.125 mg/g, i.p.; 
Sigma Aldrich, Taufkirchen, Germany) and perfused transcardially with Ringer-
solution (Braun, Melsungen, Germany) followed by 4% paraformaldehyde (PFA; 
Merck, Darmstadt, Germany). The brain, spinal cord, kidney and liver were removed, 
put in 4% PFA and post-fixed overnight at 4°C. On the next day the brains were 
placed in 30% sucrose (Merck, Darmstadt, Germany) diluted in phosphate buffered 
saline (PBS) for cryoprotection. After dehydration of the brains (2-4 days), the 
cerebellum and the brain were separately frozen on liquid nitrogen. The samples 
were stored at -80°C. Brains were cut by putting them vertically on a small metal 
plate with Tissue-tack (Sakura, Alphen aan den Rijn; Netherlands), surrounded by 
the tissue tack and placed in the cryostat (Leica, Wetzlar, Germany). When the tissue 
tack was fully frozen the whole mouse brain was cut into 30 µm thick coronal 
sections on a cryostat. The sections were kept in a 48 well plate (1 brain slice/well) in 
a storage solution (25% ethylene glycol (Sigma Aldrich, Taufkirchen, Germany) and 
25% glycerol (Merck, Darmstadt, Germany) in PBS). The plates were stored at -20°C 
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2.9.2 Luxol Fast Blue staining 
The LFB staining is a fast histological method to visualize myelin. The staining was 
done according to a well established protocol 
(http://library.med.utah.edu/WebPath/HISTHTML/MANUALS/LFB.PDF).  
The cryostat-sections were washed 4 times 15 minutes in 1xPBS, mounted on 
Superfrost plus glass slides (Thermo Fisher Scientific, Braunschweig, Germany) and 
dried. Slides were then directly put into a 1:1 alcohol- (Sigma Aldrich, Taufkirchen, 
Germany) chloroform solution (Merck, Darmstadt, Germany) over night and hydrated 
back to 95% alcohol. On the next day, the slides were put in 0.1% LFB-solution 
(Serva, Heidelberg, Germany) containing ethyl alcohol 95% (Sigma Aldrich, 
Taufkirchen, Germany) and glacial acetic acid (Merck, Darmstadt, Germany) over 
night at 56°C. Slides were first rinsed with 95% ethanol (Sigma Aldrich, Taufkirchen, 
Germany) and then with ddH2O. Slides were differentiated for 30 s by 0.05% lithium 
carbonate solution in ddH2O (Sigma Aldrich, Taufkirchen, Germany), followed by 
70% alcohol for 30 s. Slides were rinsed with ddH2O, dehydrated and coverslipped 
using DePeX (Serva, Heidelberg, Germany). 
 
2.9.3 Immunohistochemical staining  
For immunohistochemistry, a series of every 10th coronal section through the entire 
brain was taken for each marker under investigation. Free floating sections were 
washed with 1xPBS for 15 minutes 3 times, mounted on Superfrost plus glass slides 
(Thermo Fisher Scientific, Braunschweig, Germany) and dried over night. Slides 
were washed for 5 minutes 3 times in 1xPBS and then boiled in citrate buffer for 2 
minutes 3 times (1.07 mM citric acid monohydrate and 11.9 mM trisodium citrate 
dehydrate; Merck, Darmstadt, Germany). Slides were cooled down in ddH20 for 5 
minutes, washed in 1xPBS (for 5 minutes 3 times) and then incubated in 0.5 % H2O2 
in ddH2O for 30 minutes. To prevent unspecific binding, the sections were incubated 
for 1 hour in a blocking solution containing 5% normal horse serum (Jackson 
Immunoresearch, West Grove, USA) and 0.5% Triton X-100 (Sigma-Aldrich, 
Taufkirchen, Germany) in 1xPBS. Afterwards the sections were incubated in the 
primary antibody solution containing 3% normal horse serum (Dianova, Hamburg, 
Germany) and 0.5% Triton X-100 in 1xPBS for 48 hours at 4°C. The primary 
antibodies used were rabbit anti-PDGFR-α antibody (1:2000; Cell signalling, 
Frankfurt a.M., Germany), mouse anti-APC (CC-1; 1:200; Merck, Darmstadt, 
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Germany), rabbit anti-ionized calcium-binding adapter molecule 1 (IBA1; 1:1000, 
Wako, Neuss, Germany) and rabbit anti-APP (1:850; Millipore, Schwalbach, 
Germany). Slides were washed for 5 minutes 5 times and then incubated in the 
secondary antibody solution containing 3% normal horse serum, 0.5% Triton X-100 
and biotinylated goat anti-rabbit or anti-mouse antibody (1:200; Vector Laboratories, 
BA-1000) in 1xPBS. Incubation took place for 1.5 hours at room temperature 
followed by 3 washing steps for 5 minutes with 1xPBS. Next, 1.5 hour incubation at 
room temperature in the peroxidase-labeled avidin-biotin kit (Vectastain ABC Kit, 
Vector Laboratories, Burlingame, USA) followed. The solutions had to be prepared 
30 minutes prior using (ABC-Complex dilution: 2 drops of solution A + 2 drops of 
solution B in 10 ml 1xPBS). Slides were again washed for 5 minutes 3 times in 
1xPBS and then incubated in diaminobenzidine (DAB) solution (2 ml DAB + 36 μl 
H2O2 in 100 ml PBS; Sigma-Aldrich, Taufkirchen, Germany) for 1-2.5 minutes. Slides 
were washed in ddH20 and air-dried over night. Slides were put in xylol for 5 minutes 
(Chemie-Vertrieb Hannover GmbH, Hannover, Germany) and then mounted with 
non-aqueous DePeX (Serva, Heidelberg, Germany). 
For the APP staining a counterstaining with haematoxylin was performed. 
Immediately after the DAB reaction, the slides were incubated in haematoxylin 
(Sigma Aldrich, Taufkirchen, Germany) for 30 s followed by washing for 5 minutes in 
H20. Slides were dried and coverslipped as described above.  
 
2.9.4 Quantification of the cell numbers 
Two ROIs within the corpus callosum were defined. The „rostral region‟ 
encompassed bregma 1.10 to -0.10; it began with the section where the corpus 
callosum is connecting the two hemispheres and the lateral ventricle appears 
beneath and ended with the appearance of the 3rd dorsal ventricle (Figure 8A). The 
„caudal region‟ included all sections of bregma 0.94 to -2.46 and started with the 
section where the dentate gyrus is visible for the first time and ended when the 
corpus callosum is separated again (Figure 8B). Images of the corpus callosum in 
these regions were taken by a digital camera on a Zeiss light microscope (Zeiss, 
Oberkochen, Germany) connected to a computer with the Kappa imaging software 
(Kappa Optronics GmbH, Gleichen, Germany). A 40x oil objective was used for all 
images.  The single images of one brain section were merged to a continuous image 
using Adobe Photoshop CS2 (Adobe Systems, San Jose, USA) and the tool 
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„photomerge‟. In these images the area of the corpus callosum was measured and 
the cell counting was performed using Image J software (http://rsbweb.nih.gov/ij/) 







Figure 8: Illustration of the area of the corpus callosum used for quantification analysis. (A) rostral 
region bregma 1.10 to -0.10 and (B) caudal region from bregma 0.94 to -2.46. 
 
 
2.10 Intra- and Interrater reliability 
Intra- and interrater reliability was conducted to ensure the accuracy of the analyses 
of the MRI and cell counting data. All comparisons revealed significant correlations 
and were always ≥95%. SPSS for Windows version 17.0 (https://www.spss.com/de) 
was used for this analysis. 
 
2.11 Western blot analysis 
 
For western blot analysis the mice were deeply anesthetized with 0.25% 
tribromoethanol (Avertin) and sacrificed by decapitation. The brains were dissected 
out and the cortex, hippocampus and cerebellum of both hemispheres were 
separately quick frozen on dry ice. Additionally, kidney and liver were taken as 
possible control organs. Samples were stored at -80°C until use. 
 
2.11.1 Protein extraction from brain tissue 
All chemicals from Sigma Aldrich, Taufkirchen, Germany if not otherwise stated.  
The lysis buffer (pH 8.3) for protein extraction contained: 50 mM Tris HCL 
((tris(hydroxymethyl)aminomethane hydrochloride); pH 7.4), 150 mM Natrium 
chloride (NaCl; Merck, Darmstadt, Germany), 40 mM Natriumfluoride (NaF), 5 mM 
Ethylendiamin-tetraacetat (EDTA), 5 mM ethylene glycol tetraacetic acid (EGTA), 1 
mM sodium orthovanadat (Na3VO4), 1% (v/v) Igepal, 0.1% (w/v) 
Natriumdesoxycholat and 0.1% Sodium dodecyl sulfate (SDS).  
A B 
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Just before use protease inhibitors were added: 1 mM Phenylmethylsulfonylfluoride, 
10 µg/ml Aprotinin and 1 mM Leupeptin (both Roche, Penzberg, Germany).  
Either 200 µl lysis buffer for cortex samples or 150 µl for hippocampus samples was 
used for each sample. Each sample was put into a glass homogenizer (VWR, 
Darmstadt, Germany) and the lysis buffer was added, the tissue was smashed 
immediately and then put on dry ice to freeze the sample. A cycle of freezing and 
thawing was repeated 4 times which was then followed by sucking the lysed material 
up and down with a heparin syringe (10 times). The material was transferred to a 2 
ml tube (Eppendorf, Hamburg, Germany) and centrifuged (Thermo Fisher Scientific, 
Walldorf, Germany) at 12000 rpm at 4°C for 45 minutes. The supernatant was 
transferred to a fresh 2 ml tube (Eppendorf, Hamburg, Germany) and the volume was 
estimated, 10 µl were stored for protein estimation and 1/3 of 4x Laemmli (1 M Tris 
HCL (pH 8.3), 8% SDS, 40% Glycin, 20% ß-Mercaptoethanol, 0.04% Pyronin Y in 
ddH20) was added to the rest followed by a heating step for 5 minutes at 95°C or 
55°C (for PLP). Samples were stored at -80°C until use. 
 
2.11.2 Protein estimation 
The protein estimation was done using the Lowry-method. First a standard curve was 
prepared using a stock solution of albumin (1 mg/ml; Thermo Fisher Scientific, 
Walldorf, Germany) and ddH20. The final albumin concentrations were 0, 2.5, 7.5, 10, 
12.5, 15, and 20 µg/150 µl. For the samples, a dilution of 1:50 or 1:25 in ddH20 was 
prepared. 1 ml of freshly prepared Copper solution (100 parts 2% Na2CO3 in 0.1 M 
NaOH (Roth, Lauterbourg, France), 1 part 2% K-Na-Tartrat in H20 (Merck, 
Darmstadt, Germany), 1 part 1% CuSO4 in H20 (Merck, Darmstadt, Germany)) was 
added to each sample and the standard curve. Incubation time was 15 minutes. 
Next, 100 µl of Folin-Ciocalteu phenol reagent (Merck, Darmstadt, Germany) was 
added to each tube, immediately mixed and incubated for 45 minutes. To measure 
the protein concentration, a triplicate of every sample was created by 200 µl/well in a 
96 well plate. The absorbance at 595 nm was determined in the plate reader (Dynex, 





2. Materials and Methods                                                                                                         
 56 
2.11.3 Quantification of myelin proteins 
For MBP 16% Tris-Glycine precast gels and for all other proteins 4-12% Bis-Tris 
precast gels (all Invitrogen, Darmstadt, Germany) were used. 
 
Solutions: 
(1) 16% Tris-Glycine gels: 1x Tris Glycine SDS running buffer (for a 10x stock 
solution: 25 mM Tris Base, 195 mM Glycine, 0.1% SDS in ddH20; pH 8.3) and Tris-
Glycine transfer buffer (Tris Base 12 mM, 96 mM Glycine, 20% Methanol (J.T. Baker, 
Griesheim, Germany)  in ddH20) were used. Running time was set to 2.5 hours, 125 
Volt; transfer time was set for 90 minutes, 25 Volt.  
 
(2) 4-12% gels: 1x MES-Running buffer (Invitrogen, Darmstadt, Germany) and Bis- 
Tris transfer buffer (25 mM Bicine, 25 mM Bis-Tris, 1 mM EDTA in ddH20, add 20% 
of methanol; pH 7.2) were used. Running time was set to ~45-60 minutes, 200 Volt; 
transfer time was set for 90 minutes, 30 Volt.  
 
Procedure: 
Precast gels were rinsed with ddH20; tape at the bottom was removed and placed 
into the western blot chamber (Invitrogen, Darmstadt, Germany). The notched side of 
the gels faced inward of the chamber. Running buffer was filled to the whole 
chamber, the samples (15 µg/well) and SeeBlue™Plus2 Pre-Stained Protein 
Standard (10 µl; Invitrogen, Darmstadt, Germany) was loaded and the run started.  
For the transfer, the pads and nitrocellulose membrane including filter paper 
(Invitrogen, Darmstadt, Germany) were soaked in transfer buffer at least 15 minutes 
before use. When the run was completed, the gels were removed from the plastic 
tray and a sandwich of 3 pads, 1 filter paper, the gel, membrane, filter paper and 2 
pads was created. The blot module was placed in the western blot chamber and the 
transfer buffer was filled into the center until the gel-membrane sandwich was 
covered. The outer chamber was filled with H20. The transfer was started. 
When transfer was completed, the membranes were stained with Ponceau-S (Serva, 
Heidelberg, Germany) for 2-5 minutes to control the quality of the transfer. 
Membranes were rinsed with ddH20, washed with TBST (50 mM Tris, 150 mM NaCl 
and 0.5 ml/1 liter Tween20; pH 7.4) for 5 minutes 3 times and placed in 5% (w/v) 
non-fat milk in TBST for 1 hour at room temperature. Primary antibodies were diluted 
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in 5% non-fat milk in TBST and put in a 50 ml Falcon tube (Greiner, Frickenhausen, 
Germany). The antibodies used were: PLP (1:5000 (Jung et al, 1996)), CNPase 
1:1000, MBP 1:2000 (Dako, Hamburg, Germany), MOG 1:2500 (kindly provided by 
Prof. Nave). GAPDH (1:5000; Assay design; Lörrach, Germany) served as a loading 
control. Membranes were incubated in the primary antibodies over night at 4°C.  
On the next day, membranes were washed for 15 minutes 3 times in TBST and 
incubated in anti-rabbit or anti-mouse secondary antibody coupled to horseradish 
peroxidase (1:2000; Vector Laboratories, Burlingame, USA) for 1 hour at room 
temperature. Membranes were again washed for 15 minutes 3 times. 
Immunoreactive bands were visualized by incubation of membranes in a 
chemiluminescence solution containing HRP Substrate Peroxide Solution and HRP 
Substrate Luminol Reagent in a 1:1 dilution (Millipore, Billerica, MA, USA) for 5 
minutes. To detect the chemiluminescence signal, a Bio-Rad GelDoc set-up (Bio-
Rad, Munich, Germany) was used. Densitometrical analysis were done using the 
Quality One 4.6.9. software (Bio-Rad, Munich, Germany).  
 
2.12 Isolation of total RNA and quantitative real-time RT-PCR (qPCR)  
2.12.1 Isolation of RNA from frozen brain sections 
Two coronal brain sections per mouse, including the rostral and caudal part of the 
corpus callosum, were used to isolate total RNA according to the RNeasy FFPE kit 
(Qiagen, Hilden, Germany). First the sections were washed 3 times 5 minutes in 
1xPBS, then the two sections per mouse were pooled in a 2 ml tube (Eppendorf, 
Hamburg, Germany), 150 µl PKD buffer was added and mixed by vortexing followed 
by centrifugation for 1 minute at 10000 rpm (Eppendorf, Hamburg, Germany). 10 µl 
of proteinase K was added to the lower, clear phase and mixed by pipetting up and 
down. Samples were incubated first at 56°C for 15 minutes and then at 80°C for 15 
minutes followed by 3 minutes on ice before centrifugation for 15 minutes, 13500 
rpm. 16 µl of DNase Booster buffer and 10 µl of DNase I stock solution were added, 
mixed and incubated for 15 minutes at room temperature. A volume of 320 µl RBC 
buffer was added and mixed, followed by addition of 720 µl ethanol (100%). After 
samples were well mixed, 700 µl were put on an RNeasy MinElute spin column 
placed in a 2 ml collection tube. Centrifugation took place for 15 s, 10000 rpm. The 
flow-through was discarded; this step was repeated until the entire sample was used. 
Next, 500 µl RPE buffer was added to the spin column and centrifuged at 10000 rpm 
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for 15 s. The flow-through was again discarded. Again 500 µl RPE buffer was added 
to the spin column and centrifuged at 10000 rpm for 2 minutes. The spin column was 
placed in a new 2 ml collection tube and centrifuged at 10000 rpm for 5 minutes. The 
collection tube and flow-through were discarded. The spin column was placed in a 
new 1.5 ml collection tube, 30 µl RNase-free water was added and the RNA was 
eluted by centrifugation at 10000 rpm for 1 minute. RNA concentration was 
measured with a UV-spectrometer (GeneQuant II, Pharmacia Biotech, Piscataway, 
NJ,. USA) at an absorbance of λ=260 nm. The RNA concentration ranged from 36-
140 ng/µl. First strand cDNA was generated from total RNA using 10 µl RNA and 2 µl 
N6 random primers (50 µmol). Annealing took place at 70°C for 2 minutes, samples 
were cooled down on ice and the master mix containing 4 µl 5x 1st strand buffer, 2 µl 
0.1 M DTT, 1 µl dNTPs (20 mM each) and 1 µl Superskript III (200 U/µm) (all from 
Invitrogen, Darmstadt, Germany) was added. Cycling was done for 10 minutes at 
26°C, followed by 45 minutes at 50°C and 45 minutes at 55°C (UNO Thermoblock, 
Biometra, Göttingen, Germany). The cDNA was diluted 1:10 with ddH2O. 
 
2.12.2 Quantitative RT-PCR 
The relative concentrations of mRNAs of interest in different cDNA samples were 
measured out of 3 replicates using the threshold cycle method (delta Ct) for each 
dilution and were normalized to a normalization factor derived from levels of 
'housekeepers', GAPDH, beta-actin and HPRT1 mRNA, calculated with 
geNorm_win_3.5 (Vandesompele et al, 2002). Reactions were performed using 4 µl 
of diluted cDNA and 6 µl master mix containing SYBR green (ABgene, Foster City, 
CA, USA) and 5 pmol of the forward and reverse primer, respectively.   
Cycling was done for 2 minutes at 50°C, followed by denaturation at 95°C for 10 
minutes. The amplification was carried out with 45 cycles of 95°C for 15 s and 60°C 
for 60 s (Light Cycler480, Roche, Penzberg, Germany). The specificity of each primer 
pair was controlled with a melting curve analysis. For qPCR, the following primers 
were used: Mouse interleukin-1α (IL-1α) forward: 5‟-TCA ACC AAA CTA TAT ATC 
AGG ATG TGG-3‟, reverse: 5‟-CGA GTA GGC ATA CAT GTC AAA TTT TAC-3‟; 
mouse interleukin-1β (IL-1β) forward: 5‟-AAG GGC TGC TTC CAA ACC TTT GAC-3‟, 
reverse: 5‟-ATA CTG CCT GCC TGA AGC TCT TGT-3‟; mouse transforming growth 
factor-β (TGF-β) forward: 5‟-TGA CGT CAC TGG AGT TGT ACG-3‟, reverse: 5‟-GGT 
TCA TGT CAT GGA TGG TGC-3‟; mouse complement component 1, q 
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subcomponent, A chain (C1qA) forward: 5' CGG GTC TCA AAG GAG AGA GA 3', 
reverse: 5' CCT TTA AAA CCT CGG ATA CCA GT 3'; mouse triggering receptor 
expressed on myeloid cells-2 (Trem-2) forward: 5‟-ACA GCA CCT CCA GGA ATC 
AAG-3‟, reverse: 5‟-CCA CAG CCC AGA GGA TGC-3‟; mouse GAPDH forward: 5‟- 
CAA TGA ATA CGG CTA CAG CAA C-3‟, reverse: 5‟-TTA CTC CTT GGA GGC CAT 
GT-3‟; mouse beta-actin forward: 5‟-CTT CCT CCC TGG AGA AGA GC-3‟, reverse: 
5‟- ATG CCA CAG GAT TCC ATA CC-3‟; mouse HPRT1 forward: 5‟-GCT TGC TGG 
TGA AAA GGA CCT CTC GAA G-3‟, reverse: 5‟-ATG CCC TTG ACT ATA ATG AGT 
ACT TCA GGG-3‟. 
 
2.13 Statistical analysis  
 
Data were compared using 2-way or 3-way ANOVA for repeated measures including 
Bonferroni testing if applicable, and the Mann-Whitney-U-test for inter-group 
comparisons. Because the analyses concerning EPO were highly hypothesis driven, 
a one-sided Mann-Whitney-U-test was used. Significance level was set to p<0.05. 
Data are presented as mean±SEM if not stated otherwise. The data were analyzed 
using Prism5 (Graphpad Software, San Diego, CS, USA) and SPSS for Windows 
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3.1 Establishment of the cuprizone model 
 
To establish the cuprizone model, a pilot experiment was performed. As described in 
detail in the Materials and Methods section, 8 week old C57BL/6 male mice were fed 
with either normal food pellets or food pellets containing 0.2% cuprizone over a 
period of 7 weeks. The body weight of mice and the motor performance on a rota-rod 
(constant speed 16 rpm) were monitored. Both experimental groups gained weight 
over the 7 weeks (Figure 9; 2-way ANOVA for repeated measures, F6,492=746,14, 
P<0.001). Until week 4 the mice were not impaired in their motor performance 
(Figure 10A), to make the motor task more difficult the rota-rod protocol was 
changed; the rotation of the rotating drum started with a speed of 4 rpm and 
accelerated to 40 rpm within 5 minutes. Based on the challenge of the new rota-rod 
protocol a decrease in the performance in both groups was observed (Figure 10B). 
However, there was no difference between the groups. To check for demyelination a 
LFB staining was performed. The cuprizone-fed mice had a normal myelinated 
corpus callosum (Figure 11). Based on the histology and data for the body weight of 
mice a second pilot experiment was designed. Cuprizone was administered via food 
















                          Figure 9: First pilot experiment. Body weight of mice fed with normal  
                               food pellets (Placebo) or food pellets containing 0.2% cuprizone over  
                               the whole experimental time. Mean±SEM presented; N= 42-44/group. 
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Figure 10: First pilot experiment. (A) Rota-rod performance of mice from weeks 1 to 4 with a constant 
speed of 16 rpm. (B) Rota-rod performance of mice from weeks 5 to 7 with accelerated speed from 4 














                       
 
                      Figure 11: First pilot experiment. Presentation of a LFB-staining in the  
                      corpus callosum of a mouse fed for 6 weeks with normal food pellets  
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In the second pilot experiment, the application of cuprizone via pellets or ground 
chow was compared (for the experimental design see Materials and Methods section 
2.5.1). The main readout was body weight of mice. This parameter was significantly 
influenced by the cuprizone feeding of mice via ground chow (3-way ANOVA for 
repeated measures, F(2,3)=55,80, P=0.004). Already 4 days after the application of 
0.2 or 0.3% cuprizone mixed into ground chow these mice lost weight. The body 
weight further decreased and stayed on a constantly lower level until the end of the 
experiment (Figure 12A). Two mice fed with 0.3% cuprizone and one mouse of the 
0.2% diet-group died on day 19. In comparison no weight loss and even a gain of 
weight over time was observed in mice fed 0.2% cuprizone via food pellets (Figure 
12B; 2-way ANOVA for repeated measures, F(6,24)=131,75, P<0.001). Toxicological 
analysis of the food pellets confirmed that cuprizone was present, intact and active 
(see Supplement 6.1; performed in the Department of Pharmacology and Toxicology 
at the University hospital Göttingen, Germany). Based on these findings all future 













Figure 12: Second pilot experiment. (A) Body weight of mice fed with normal ground chow (Placebo) 
or cuprizone mixed into ground chow. Cuprizone feeding significantly influenced the body weight of 
mice (3-way ANOVA F(2,3)=55,80, P=0.004). (B) Body weight of mice fed with normal food pellets 






3. Results                                                                                                                                
 63 
9 15 180 6
Weeks
Normal food / no treatment
Cuprizone feeding (0.2%)
Placebo injections (PL)
EPO (5000 IU/kg bw i.p.)
Sacrifice of mice
3.2 Effect of EPO on re- and demyelination 
3.2.1 Overview of analyzed parameters 
In the following tables, an overview of the analyzed parameters in the two studies 
investigating the effect of EPO on remyelination (Table 6) and demyelination (Table 
7) is presented. In the study which analyzed the effect of EPO on remyelination 
(Table 6) mice were not sacrificed at weeks 6 and 15, therefore only behavioral 
analyses were performed at these time points. The lack of data at some of the other 
time points in both studies is due to the results obtained from previous time points or 
the other parameters at that time. Additional analyses were not thought to give 












Table 6: Effect of EPO on remyelination. Overview of the parameters analyzed at different time 
points. (ABR: auditory brain stem response; WB: western blot; MTR: magnetization transfer ratio)  
 
Parameters analyzed Week 6 Week 9 Week 15 Week 18 
Rota-rod Done Done Done Done 
Beam balance Not performed Not performed Done Done 
Startle response Done Done Done Done 
ABRs - Not performed - Done 
Protein analysis (WB) - Done - Done 
MRI 
analysis 
Volumetry - Not performed - Done 
%MTR - Not performed - Not performed 
Haematocrit - Done - Done 
Immunohistochemistry - Not performed - Not performed 
 
 
    
 
 
                                             




Normal food / no treatment
Cuprizone feeding (0.2%)
Placebo injections (PL)
EPO (5000 IU/kg bw i.p.)
Sacrifice of mice
 















Parameters analyzed Week 6 Week 9 
Rota-rod Done Done 
Beam balance Done Done 
Startle response Done Done 
ABRs Not performed Not performed 
Protein analysis (WB) Not performed Not performed 
MRI 
analysis 
Volumetry Done Done 
%MTR Done Done 
Haematocrit Done Done 




3.2.2 Effect of EPO on remyelination 
3.2.2.1 Basic observations under cuprizone and EPO treatment 
Cuprizone application took place either once over 6 weeks followed by a 
remyelination phase of 3 weeks combined with intra-peritoneal placebo or EPO 
injections or repeatedly; a second cycle of cuprizone feeding and a second 
remyelination phase combined with placebo/EPO injections occurred after the first 
recovery phase (see Materials and Methods section 2.5.2.2). Cuprizone feeding 
significantly decreased the body weight over time (3-way ANOVA for repeated 
measures, F(1,55)=212,28, P<0.001). A fast recovery in the first and even second 
remyelination phase was observable (Figure 13A and B). However, even in the third 
recovery week (weeks 9 and 18) the body weight of cuprizone-fed mice was always 
below the control groups. Interestingly, in the second demyelination phase (weeks 
10-15) the body weight of EPO-treated cuprizone mice did not decline as much as 
Table 7: Effect of EPO on demyelination. Overview of the 
parameters analyzed at different time points. (ABR: auditory 
brain stem response; WB: western blot; MTR: magnetization 
transfer ratio) 
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compared to the placebo-treated cuprizone mice. However, this difference did not 






Figure 13: Effect of EPO on remyelination. (A) Body weight of mice in the single feeding group; N=20; 
(B) body weight of mice in the repeated feeding group; N=15-25. The cuprizone mice showed a 
significantly lower body weight over time compared to the controls (3-way ANOVA for repeated 




Evaluation of the haematocrit at weeks 9 and 18 revealed a significant increase by 






















































A                   Week 9   B                 Week 18 
Figure 14: Effect of EPO on remyelination. Haematocrit of mice 
at (A) week 9; N=11-15 and (B) week 18; N=7-10. Mean±SEM 
presented; PL=placebo; EPO=erythropoietin. 
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3.2.2.2 Motor coordination and balance under cuprizone and EPO treatment 
The results of the accelerated rota-rod, which is a relatively crude test for motor 
function, showed that all mice improved their performance over time (Figure 15; 3-
way ANOVA for repeated measures, F(18,990)=35.97, P<0.001). Cuprizone did not 













                  
 





Beam balance is a test for vestibulomotor function in mice. At week 15, directly after 
the second cycle of demyelination, cuprizone/placebo mice needed significantly more 
time to cross the 10 and 8 mm beam compared to the control group (Mann-Whitey U-
test, P≤0.003). EPO treatment of cuprizone mice significantly improved the 
performance on the 8 mm beam (Figure 16; Mann-Whitey U-test, P=0.015). After the 
second recovery phase, cuprizone-fed mice had a higher duration to cross the beam 





Figure 15: Effect of EPO on remyelination. Falling latency on the 
accelerated rota-rod (4-40 rpm). Grey boxes indicate the recovery phases. 
N=14-25; mean ±SEM presented; PL=placebo; EPO=erythropoietin. 
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Figure 16: Effect of EPO on remyelination. The beam balance test was performed at weeks 15 and 18. 
A 10 and 8 mm diameter beam was used and the time to cross the beam (duration) was recorded.  




3.2.2.3 Startle response of mice 
The observation of a disturbed behavior in the pre-pulse-inhibition test excluded the 
analysis of these data (therefore data not shown), and led to the assessment of 
hearing using the startle response test. This test measures the startle response of 
mice to acoustic stimuli in a range of 65 to 120 dB. At weeks 6, 15, and 18, both 
cuprizone groups showed a significantly reduced startle response without any further 
influence of EPO (Figure 17; 2- or 3-way ANOVA for repeated measures, P≤0.001). 
To further analyze whether this is in fact a result of an impaired hearing ability of the 
mice, acoustic evoked potentials were measured (collaboration with Nicola Strenzke, 
Department of Otorhynolaryngology, University hospital Göttingen, Germany). 
However, no group differences were observed in the amplitude or latency of the 
recorded ABRs at week 18 (Figure 18).  
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Figure 17: Effect of EPO on remyelination. Assessment of hearing measured by the startle response 
of mice to acoustic stimuli ranging from 65 to 120 dB. This test was performed at weeks 6, 9, 15, and 













Figure 18: Effect of EPO on remyelination. Assessment of hearing by the recording of acoustic evoked 
brain stem responses to 20 Hertz stimuli at week 18; N=6. PL=placebo; EPO=erythropoietin. 
 
 













































































































































































































































































3.2.2.4 Analysis of myelin proteins in the hippocampus and cortex 
Besides investigating physical and behavioral parameter, changes related to myelin 
were assessed on protein level. The cortex and hippocampus were the regions of 
interest for myelin protein analysis. At week 9, after the first remyelination phase of 3 
weeks, CNP, MOG (myelin oligodendrocyte glycoprotein) and MBP were significantly 
decreased in the cortex of cuprizone mice (Figure 19; Mann-Whitey U-test, PL vs. 
Cuprizone PL, P<0.01). PLP showed the same trend but failed to be significant. In 
contrast, all these myelin proteins were not affected in the hippocampus of 
cuprizone-fed mice at this time point (Figure 19). EPO did not show any effect. 
 
Figure 19: Effect of EPO on remyelination. Analysis of the myelin proteins: CNP (2‟-3‟-cyclic nucleotide 
3'-phosphodiesterase), MOG (myelin oligodendrocyte glycoprotein), PLP (proteolipid protein) and 
MBP (myelin basic protein) in the cortex and hippocampus at week 9; N=7; mean±SEM presented; 
PL=placebo; EPO=erythropoietin. 
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At week 18, after the second recovery phase, all myelin proteins in both cortex and 
hippocampus were significantly reduced (Mann-Whitey U-test, PL vs. Cuprizone PL, 
P<0.01). No effect of EPO was present (Figure 20).  
Figure 20: Effect of EPO on remyelination. Analysis of the myelin proteins: CNP (2‟-3‟-cyclic nucleotide 
3'-phosphodiesterase), MOG (myelin oligodendrocyte glycoprotein), PLP (proteolipid protein) and 
MBP (myelin basic protein) in the cortex and hippocampus at week 18; N=8-10; mean±SEM 




3.2.2.5 Volumetrical analysis of cuprizone-fed mice 
At the end of the experiment (week 18) MRI took place. Cuprizone-fed mice did not 
show any sign of brain atrophy as analyzed by T1-maps (Figure 22; Brain matter). In 
all cuprizone mice an obvious enlargement of the ventricular system was apparent 
(as illustrated in Figure 21), although it was not significant. High variations in the 
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measurement of the ventricular volume within the cuprizone groups became 











































Figure 22: Effect of EPO on remyelination. Volumetrical analysis of the total brain, brain matter, 
hippocampus and ventricular system at week 18; N=6; mean±SEM presented; PL=placebo; 
EPO=erythropoietin. 
Figure 21: Effect of EPO on remyelination. T2-
weighted sample image to illustrate the 
enlargement of the ventricular system of mice 
fed with 0.2% cuprizone. Images kindly 
provided by Susann Boretius. 
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In summary, the study of investigating the effect of EPO on remyelination showed 
that cuprizone feeding had a potent effect on the body weight of mice, vestibulomotor 
function, myelin protein levels in the brain and brain volumetrical parameters 
(ventricular system). EPO application had a slight effect on the body weight of mice 
during the second demyelination phase and significantly improved the performance 
in the beam balance task at week 15. No further beneficial effect of EPO was 
present.  
  
3.2.3 Effect of EPO on demyelination 
3.2.3.1 Basic observations under cuprizone and EPO treatment 
The cuprizone diet was again applied for 6 weeks and was followed by a 
remyelination phase of 3 weeks. In weeks 4-6 of cuprizone feeding placebo/EPO 
treatment was applied (see experimental scheme in Materials and Methods section 
2.5.3). The body weight of mice was significantly reduced by the cuprizone feeding 
(3-way ANOVA for repeated measures, F(1,56)=235,61, P<0.001) and returned to 
comparable levels to the controls after 3 weeks recovery (Figure 23A). The 
haematocrit of EPO-treated mice in both the control and cuprizone group was 
significantly increased at week 6 (Mann-Whitey U-test, P≤0.001), directly after the 
termination of the treatment. Both groups reached normal levels after the recovery 











Figure 23: Effect of EPO on demyelination. (A) Body weight of mice. Cuprizone-fed mice had 
significantly lower body weight over time compared to controls (3-way ANOVA for repeated measures, 
F(1,56)=235,61, P<0.001); N=15-26; mean±SD presented. Grey box indicates the recovery phase. (B) 
Haematocrit of mice at weeks 6 and 9; EPO significantly enhanced the haematocrit at week 6 (Mann-






















































3.2.3.2 Motor coordination and balance under cuprizone and EPO treatment 
At baseline, before the cuprizone feeding started, the performance of mice on the 
rota-rod was comparable and all groups showed an improvement of the performance 
from day 1 to 2 (Figure 24, 3-way ANOVA for repeated measures, F(2,100)=5.90, 
P=0.017). 6 weeks after cuprizone initiation all mice showed a comparable 
performance on the rota-rod and improvement over the 3 testing days (Figure 25A, 3-
way ANOVA for repeated measures, F(2,194)=12.57, P<0.001). No differences 

































Figure 25: Effect of EPO on demyelination. Falling latency in a 3-day rota-rod paradigm (acceleration 
4-40 rpm) at (A) week 6; all mice improved their performance over time (3-way ANOVA for repeated 
measures, F(2,194)=12.57, P<0.001); N=24-26 and (B) week 9; N=15. Mean±SEM presented; 
PL=placebo; EPO=erythropoietin. 
 
                              Baseline     
Figure 24: Effect of EPO on demyelination. 
Baseline performance in a 2-day rota-rod 
paradigm (acceleration 4-40 rpm). N=26; 
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In the beam balance task, all mice at baseline showed a comparable duration to 
cross the 10 and 8 mm beam (Figure 26). At week 6, the cuprizone-fed mice needed 
significantly longer time to cross the 10 and 8 mm beam (Mann-Whitey U-test, PL vs. 
Cuprizone PL, P<0.001). However, EPO-treated cuprizone mice improved their 
performance on the 10 mm beam and significantly on the 8 mm beam (Figure 27; 
Mann-Whitey U-test, P=0.004). At week 9, both cuprizone groups recovered and 

















                            
                            























Figure 27: Effect of EPO on demyelination. Beam balance test performed on the 8 and 10 mm beam 
at weeks 6 and 9. At week 6, cuprizone mice showed a higher duration to cross the beam (Mann-
Whitey U-test, PL vs. Cuprizone PL, P<0.001). N=14-26; mean±SEM presented; PL=placebo; 
EPO=erythropoietin. 
Figure 26: Effect of EPO on demyelination. Baseline 
performance on the 8 and 10 mm beam. The time to 
cross the beam (duration) was measured. N=24-26; 
mean±SEM presented; PL=placebo; EPO=erythropoietin. 
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3.2.3.3 Startle response of mice 
To evaluate the startle response of mice in the current experimental conditions and to 
prove the previous observations, this test was performed again. A similar picture was 
present; whereas all groups showed a similar startle response at baseline (Figure 
28), at week 6, cuprizone feeding significantly reduced the startle response of mice 
(Figure 29; 3-way ANOVA for repeated measures, F(1,87)=61.65, P<0.001). This effect 



















Figure 29: Effect of EPO on demyelination. Assessment of hearing at weeks 6 and 9 by 
measuring the startle response of mice to acoustic stimuli ranging from 65 to 120 dB. At 
week 6, cuprizone mice showed a significant reduced startle response (3-way ANOVA 
for repeated measures, F(1,87)=61.65, P<0.001). N=15-26; mean±SEM presented; 
PL=placebo; EPO=erythropoietin; AU=arbitrary unit.  
 
Figure 28: Effect of EPO on demyelination. 
Assessment of hearing at baseline. The 
startle response of mice to acoustic stimuli 
ranging from 65 to 120 dB was measured. 
N=26; mean±SEM presented; PL=placebo; 
EPO=erythropoietin; AU=arbitrary unit.  
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3.2.3.4 Volumetrical analysis of cuprizone-fed mice 
At two time points, weeks 6 and 9, MRI was performed. As seen already in the 
previous experiment, cuprizone did not affect the brain matter of mice at any time 
point (Figure 30). Interestingly, the volume of the hippocampus of cuprizone mice 
was significantly reduced at week 6 (Mann-Whitey U-test, PL vs. Cuprizone PL, 
P=0.005) and returned back to control levels at week 9. The brain volume of the 
cuprizone/placebo mice was significantly enlarged at week 6 (Mann-Whitey U-test, 
PL vs. Cuprizone PL, P=0.005). The analysis of the ventricular system (lateral 
ventricle left and right and third ventricle) showed a huge increase of the ventricular 
volume of cuprizone mice at week 6 (Mann-Whitey U-test, PL vs. Cuprizone PL, 
P=0.005). This effect was significantly reduced by EPO (Figure 30). After a recovery 
of 3 weeks the ventricles were still enlarged without any further effect of EPO.  
 
 
Figure 30: Effect of EPO on demyelination. Volumetrical analysis of the brain volume, brain matter, 
hippocampus, lateral ventricles and the third ventricle at weeks 6 and 9. N=4-6; mean±SEM 
presented; PL=placebo; EPO=erythropoietin. 
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Additionally, the %MTR, a measurement of the degree of myelination, was analyzed. 
This value was significantly decreased in cuprizone mice at week 6 (Mann-Whitey U-
test, PL vs. Cuprizone PL, P=0.01) whereas the cuprizone/EPO group showed 
slightly higher levels (Figure 31). At week 9, this value was still not completely back 
to control levels in both the cuprizone placebo and EPO group. 
 
 
    








3.2.3.5 Examination of mature and precursor oligodendrocytes at week 6 
For a better understanding of the observed effect of EPO on behavioral and imaging 
parameters at week 6, this time point was selected to perform immunohistochemical 
analysis for oligodendrocytes, microglia and axonal degeneration. Oligodendrocytes 
were visualized by immunohistochemistry using the antibodies PDGFR-α and CC-1 
(anti-APC). As illustrated in Figure 32, PDGFR-α nicely stains the cell body and 
processes of precursor oligodendrocytes in the brain sections whereas CC-1 (anti-
APC) stains the cell body and cytoplasm of mature oligodendrocytes (Figure 33). 
Both were analyzed in the corpus callosum 6 weeks after cuprizone initiation. 
Precursor oligodendrocytes were significantly increased within the rostral and caudal 
part of the corpus callosum upon cuprizone feeding (Figure 32 and 34 upper panels; 
for both regions: Mann-Whitey U-test, PL vs. Cuprizone PL, P<0.001). No clear effect 
of EPO was observable, although a trend of a slight decrease of precursor 
oligodendrocytes was visible (Figure 34). Mature oligodendrocytes were heavily 
depleted in the entire corpus callosum (Figure 33 and 34 lower panels; for both 
regions: Mann-Whitey U-test, PL vs. Cuprizone PL, P<0.001). EPO was not able to 
counteract this effect (Figure 34).  
 
 
Figure 31: Effect of EPO on demyelination. 
Analysis of the % magnetization transfer ratio 
(%MTR) at weeks 6 and 9. N=4-6; 
mean±SEM presented; PL=placebo; 
EPO=erythropoietin.                      
 


















                                
 



























Figure 33: Effect of EPO on demyelination. Mature 
oligodendrocytes stained by CC-1 (anti-APC) in the corpus 
callosum of a control mouse (left) and a cuprizone mouse (right). 
Scale bar 50µm. 
 
Figure 32: Effect of EPO on demyelination. Precursor 
oligodendrocytes stained by PDGFR-α in the corpus callosum of 
a control mouse (left) and a cuprizone mouse (right). Scale bar 
50µm.  
 


































































































                    
 
 





3.2.3.6 Analysis of microglia and axonal degeneration at week 6 
At week 6, microglia were stained with IBA-1 and quantified within the corpus 
callosum. As illustrated in Figure 35, microglia in control mice were highly ramified 
(left), whereas cuprizone-fed mice changed their morphometrics to amoeboid-like 
cells (right). Quantification of these cells showed a dramatic increase in cuprizone 
mice in both regions of the corpus callosum (Figure 36; Mann-Whitey U-test, PL vs. 
Cuprizone PL, P<0.001). EPO decreased the number of microglia, slightly in the 
Figure 34: Effect of EPO on demyelination. Quantification of 
PDGFR-α
+
 precursor (upper panels) and APC
+
 mature 
oligodendrocytes (lower panels) in the rotral and caudal corpus 
callosum at week 6. Both cell types were significantly 
influenced upon cuprizone feeding (Mann-Whitey U-test, PL 
vs.Cuprizone PL, P<0.001). N=9-11; mean±SEM presented; 
PL=placebo; EPO=erythropoietin. 
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Figure 36: Effect of EPO on demyelination. Quantification of IBA-1
+ 
microglia in the rostral and caudal corpus callosum. Microglia were 
significantly elevated upon cuprizone feeding (Mann-Whitey U-test, 
PL vs. Cuprizone PL, P<0.001). N=7-11; mean±SEM presented; 
PL=placebo; EPO=erythropoietin. 
 
Figure 35: Effect of EPO on demyelination. Highly ramified 
microglia in the corpus callosum of control mice (right) and 
amoeboid-like microglia in cuprizone mice (left) at week 6. Scale 
bar 50µm. 
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Axonal degeneration can be analyzed on the immunohistochemical level using the 
APP antibody. Whereas no APP+ spheroids were visible at week 6 in control mice 
(Figure 37 left), distinct accumulations were present in cuprizone mice (Figure 37 
right; arrows). Quantification revealed a clear increase of APP+ accumulations in the 
corpus callosum of cuprizone mice (Figure 38; Mann-Whitey U-test, PL vs. Cuprizone 
PL, P<0.001). A decrease of axonal degeneration was visible in the caudal and more 
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Figure 38: Effect of EPO on demyelination. Quantification of 
APP
+
 accumulations in the rostral and caudal corpus callosum. 
Significant increase of axonal degeneration upon cuprizone 
(Mann-Whitey U-test, PL vs. Cuprizone PL, P<0.001). N=8-11; 
mean±SEM presented; PL=placebo; EPO=erythropoietin. 
 
Figure 37: Effect of EPO on demyelination. APP
+ 
accumulations in the corpus callosum of control (left) and 
cuprizone (right) mice at week 6. Arrows point to positive 
accumulations. Scale bar 20µm. 
 

















































































3.2.3.7 Expression of cytokines and mircoglia activity markers at week 6 
To further evaluate the inflammatory component of the cuprizone model and potential 
EPO effects in this context, quantification of brain mRNA levels of cytokines and 
micoglial activity markers was performed. The analyzed cytokines, IL-1α and IL-1β, 
showed a strong upregulation upon cuprizone feeding (Figure 39; Mann-Whitey U-
test, PL vs. Cuprizone PL, P<0.001). Similarly, two microglial activity markers, C1qA 
and Trem-2, showed the same pattern (Figure 39; Mann-Whitey U-test, PL vs. 
Cuprizone PL, P≤0.02). In contrast, TGF-β, a protective growth factor, was 
downregulated by cuprizone (Mann-Whitey U-test, PL vs. Cuprizone PL, P=0.026). 
Even though, in the most cases a small tendency of a counter regulation of EPO 


















          
 
Figure 39: Effect of EPO on demyelination. Quantification of cytokines (IL-1α, IL-1β & 
TGF-β) and microglial activity marker (C1qA, Trem-2) on mRNA level at week 6. 
Expression levels are normalized to a normalization factor (NF) and significantly 
influenced by cuprizone (Mann-Whitey U-test, PL vs. Cuprizone PL, P<0.05). N=5-11; 
mean±SEM presented; PL=placebo; EPO=erythropoietin. 
 




The present thesis investigated whether EPO modulates cuprizone-induced de- 
and/or remyelination processes in the corpus callosum, including related changes at 
the behavioral, imaging, immunohistochemical, mRNA expression and myelin protein 
levels. The selection of the cuprizone mouse model was based on several important 
characteristics. As elaborated in the introduction, the feeding of mice with the toxin 
cuprizone results in a marked demyelination of the corpus callosum, as well as other 
brain regions such as hippocampus, cortex and cerebellum. The advantage of this 
model, compared to EAE models, is to study myelination processes relatively 
isolated from direct immune-inflammatory influences. Moreover, the model has a 
recovery potential, allowing for investigation of events related to de- and 
remyelination. An intact BBB in cuprizone-fed mice excludes massive infiltration of 
peripheral immune cells. Two study designs were chosen to investigate the effect of 
EPO in the most clinical relevant manner: (1) EPO treatment started directly after the 
damage fully occurred (with the beginning of remyelination), or (2) EPO was given at 
an earlier time point when the first signs of damage appeared (during the 
demyelination phase). The hypothesis of the thesis was that EPO modulates the 
cuprizone-induced changes in all readouts analyzed. 
 
4.1 Establishment of the cuprizone model 
 
First the cuprizone mouse model had to be established. Oriented by the available 
publications about the cuprizone model (see Tables 1-5), 8 week old C57BL/6 male 
mice were used. In the first pilot experiment, the mice were fed with either normal 
food pellets or food pellets containing 0.2% cuprizone. This was done to make the 
application of cuprizone more precise and practical and avoid unnecessary dispersal 
of the toxin in the experimental room. Surprisingly, the feeding of mice with the 
cuprizone-containing food pellets resulted in neither the known cuprizone-induced 
decrease of body weight, nor in the demyelination of the corpus callosum. However, 
a toxicological analysis proved that cuprizone was present, intact and active in the 
food pellets (see Supplement 6.1). After a careful re-screening of the literature, it 
became clear that cuprizone was always administered with ground chow and was 
applied only once via drinking water (Zatta et al, 2005). Importantly, no publication 
explicitly stated that cuprizone has to be administered via ground chow.  
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A second pilot experiment was designed in which a small number of 6-7 week old 
mice were either exposed to ground chow containing 0.2 or 0.3% cuprizone or 0.2% 
cuprizone-containing food pellets. The higher dose was additionally used to control 
for the efficacy of different cuprizone doses. Younger mice were used to clarify if 
these mice were more susceptible to cuprizone intoxication. Monitoring of the body 
weight of mice clearly revealed a loss of body weight in mice fed with cuprizone 
mixed into ground chow, but not in the mice fed with cuprizone-containing food 
pellets, although these mice were even younger. A higher mortality rate of 0.3% 
cuprizone-fed mice indicated an increased severity of this dose. Furthermore, mice at 
an age below 8 weeks seemed to be highly susceptible to the toxin. With these data, 
it was concluded that there must be other routes of cuprizone uptake such as via e.g. 
skin or respiration to induce demyelination in mice. For all following experiments, 8 
week old C57BL/6 male mice and 0.2% cuprizone mixed into standard ground chow 
were used.  
 
4.2 Effect of EPO on remyelination 
 
Two aspects were the focus of the experiments concerning the effect of EPO on 
remyelination: (1) The potential of EPO to support reparative mechanisms during 
remyelination after acute myelin damage and (2) after repeated myelin damage. The 
latter aspect was related to clinically relevant situations such as in a relapsing-
remitting disease course in MS.  
The body weight changed as expected even during the repeated de- and 
remyelination phase. Interestingly, the body weight of EPO-treated cuprizone mice 
decreased less in the second demyelination cycle compared to placebo-treated 
cuprizone mice, but this finding was not significant. Even in the second demyelination 
phase, no impairment in general motor performance could be found as evaluated by 
the accelerated rota-rod test. These two parameters (body weight and motor 
performance) show a general physical robustness of the mice even after a repeated 
cuprizone challenge. The measurement of haematocrit to monitor the effect of EPO 
on erythrocytes showed that cuprizone feeding did not interfere with this effect of 
EPO. Interestingly, as shown once before (Skripuletz et al, 2010b) the beam balance 
task turned out to be sensitive enough to detect cuprizone-induced changes in motor 
coordination and balance. What was even more striking was the fact that the task 
was able to reveal protective effects of EPO at week 15. This finding, together with 
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the observation that EPO led to a reduced loss of body weight in the second 
demyelination phase, suggests a protective effect of EPO in this experimental set-up.   
 
Although a final explanation for reduced startle reactivity of mice upon cuprizone 
feeding is not yet possible, a deficit in the hearing ability of cuprizone-fed mice could 
be ruled out as a possible explanation. Additional analysis considering the influence 
of body weight of mice in this test did not explain the finding either. Interestingly, a 
reduced startle response was already seen in another study, though without further 
clarification of this observation (Xu et al, 2009). Furthermore, a higher number of 
mice showing freezing behavior to click stimuli was observed upon cuprizone 
intoxication, but the strength of the freezing was not specified (Franco-Pons et al, 
2007). Cuprizone-induced demyelination that may lead to connectivity problems 
between brain regions and/or a generally poorer physical condition of the mice could 
be just two hypothetical explanations. Further analyses are needed to clarify the 
observed phenomenon.  
 
Interestingly, the analysis of different myelin proteins after the first recovery period 
(week 9) showed a severe depletion of the proteins in the cortex, whereas 
remyelination in the hippocampus was already progressed and showed no 
differences between control and cuprizone groups. After the second recovery phase 
(week 18), all investigated myelin proteins were heavily reduced in both cortex and 
hippocampus. However, at both time points no effect of EPO was present. The 
differences between the cortex and hippocampus at week 9 could be explained, 
either by a different susceptibility of the brain regions to cuprizone or by a better 
recovery potential in the hippocampus. A hint of a different susceptibility to cuprizone 
between brain regions was given by a study showing more severe demyelination in 
the cortex compared to the corpus callosum (Skripuletz et al, 2008). The lack of a 
recovery of the myelin proteins in both the cortex and hippocampus at week 18 could 
be caused by an exhaustion of the myelin protein expression capacity by cuprizone 
at this time point. However, to support this statement, data at e.g. the 15 week time 
point would be needed to see the time course of the myelin protein expression. An 
expression analysis of myelin proteins in the cortex and hippocampus in the 
cuprizone model is not yet published and excludes a comparison of the presented 
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data to other studies. The raised statements above are therefore speculative but 
were not topics in question to be further analyzed in this study.  
The absence of an EPO effect on myelin proteins is surprising, especially because in 
other models e.g. for juvenile brain trauma, an effect of EPO on myelin proteins was 
demonstrated (Sargin et al, 2009). Discrepancies compared to this study can be 
explained by different actions of EPO in different disease models and/or the age of 
mice at the time point of EPO treatment. In the study by Sargin et al (Sargin et al, 
2009), EPO application took place in 4 week old mice, whereas in the current study 
the mice were 14 weeks old. Accumulating findings in our lab support the idea that 
age can play a role at the time of EPO application. In addition to this, other reasons 
for a lack of an EPO effect can be discussed. The analysis was restricted to the 
cortex and hippocampus; clearer results in this study may have come about by 
studying the myelin fraction of the brain. The time points of investigation were 
restricted to 9 and 18 weeks to analyze the effect of EPO on remyelination potential, 
but these may not be the most relevant ones to see EPO effects in this readout. In 
general, it could be further speculated that EPO application was not performed in the 
most relevant time window in this model. On the other hand, the specific cuprizone-
induced damage of myelin proteins could perhaps not have been counteracted by 
EPO.  
 
Enlarged ventricles are a common feature in the cuprizone model (Carlton, 1966; 
Carlton, 1967; Kesterson & Carlton, 1970). For instance, elevated ventricles were 
reported by the first and so far only cuprizone study of repeated feeding (Pattison & 
Jebbett, 1973). Although the design of this study differs compared to the present 
study, the influence of cuprizone on the ventricular system could be found here as 
well. EPO did not have an effect on this readout. However, the MRI analysis was 
restricted to the end-point of the experiment, making it difficult to draw any final 
conclusions regarding EPO action on this parameter.  
 
To conclude, cuprizone had a potent effect on all parameters analyzed except the 
rota-rod performance of mice and acoustic evoked potentials. EPO showed a 
protective effect concerning body weight loss and vestibulomotor performance. 
However, analyses on an immunohistochemical and protein level at comparable time 
points are missing and make a conclusion of underlying mechanisms impossible. At 
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the end-point of this experiment (18 weeks), lack of an EPO effect in the MRI 
parameter, myelin protein analysis and beam balance task suggest that the 
cuprizone-induced damage at this time point may be too progressed or the recovery 
potential is still too fast to detect an EPO effect.  
 
4.3 EPO effect on demyelination 
 
In this experimental set-up, EPO had no influence on the weight loss of cuprizone-fed 
mice. The motor performance on the rota-rod confirmed the previous finding that 
mice fed with cuprizone do not have a severe motor phenotype. This has already led 
to the development of a more sophisticated motor task for this model by others 
(Liebetanz & Merkler, 2006). Interestingly, at week 6 EPO again improved the 
performance of cuprizone mice in the beam balance task, whereas at week 9 no 
differences were obtained between any groups showing a high recovery potential. 
Based on different time points investigated, direct comparison to the effect of EPO 
observed in the beam balance task in the previous experiment is difficult. 
 
Volumetrical analysis at week 6 again showed no influence of cuprizone on brain 
matter. Interestingly, at this time point the hippocampal volume was reduced upon 
cuprizone feeding. In MRI images, as well as in histological sections, the 
hippocampus often appeared to be squeezed, which could be explained by the 
significant enlargement of the ventricular system by cuprizone. The ballooned 
ventricles may push the surrounding tissue, including the hippocampi, against the 
skull. The EPO-treated cuprizone mice had significantly smaller ventricles compared 
to the cuprizone/placebo mice.  
So far, just one study intensively investigated the possible reasons for hydrocephalus 
in the cuprizone mouse model (Kesterson & Carlton, 1970). In this study, the authors 
suggested that hydrocephalus occurs secondary to the stenosis of the aqueduct of 
Sylvius, which may result from pressure exerted by the surrounding edematous 
tissue. The authors further claimed a normal secretion of cerebral spinal fluid. This is 
of course just one possible explanation and was unfortunately never in the interest of 
others to be further studied. However, EPO treatment during the demyelination 
phase may have dampened the degenerative effect of cuprizone on the brain tissue 
and therefore reduced the closure of the aqueduct of Sylvius. This could then explain 
the smaller ventricle volume.  
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Since the %MTR, a MRI readout, correlates with myelination in the corpus callosum 
(Merkler et al, 2005), the reduction of this value in cuprizone-fed mice at week 6 
suggests demyelination occurring within the corpus callosum. EPO had the tendency 
to increase this value. This is in agreement with studies showing better myelin sheath 
preservation in different disease models by EPO (Gorio et al, 2002; Iwai et al, 2010; 
Kumral et al, 2007; Li et al, 2004; Liu et al, 2011; Vitellaro-Zuccarello et al, 2007; 
Yamada et al, 2011). Additionally, as shown before, immunohistochemical analysis 
revealed a severe depletion of mature oligodendrocytes by cuprizone within the 
corpus callosum without an additional effect of EPO. At the same time, precursor 
oligodendrocytes were significantly increased by cuprizone but only slightly reduced 
under EPO treatment. Indeed, studies which used other animal models found a clear 
effect of EPO on proliferation and maturation of oligodendrocytes (Iwai et al, 2010; 
Vitellaro-Zuccarello et al, 2007; Zhang et al, 2005; Zhang et al, 2010). The lack of an 
EPO effect on oligodendrocytes in the present study might be explained by the time 
point and brain region selected for the analysis. However, it could be more likely 
assumed that the mechanism of cell death induced by cuprizone feeding simply 
cannot be counteracted by EPO. This is supported by a recent publication, which 
showed an advantageous influence of vitamin D3 treatment on demyelination in the 
cuprizone model but also failed to demonstrate an effect on mature oligodendocytes 
(Wergeland et al, 2011).  
It is important to note that the experimental condition (animal model) and exact EPO 
application (dose, time point, age of mice) seem to fundamentally influence the 
outcome of EPO treatment.  
 
The present study confirmed the known cuprizone-induced upregulation of microglia 
within the corpus callosum (Arnett et al, 2001; Gudi et al, 2009; Hiremath et al, 1998; 
Lindner et al, 2009; Mason et al, 2004; Merkler et al, 2005; Morell et al, 1998) and 
showed that EPO treatment counteracted this effect. Interestingly, this result was 
more prominent in the caudal than rostral region of the corpus callosum. A separate 
analysis of the rostral and caudal corpus callosum was based on findings of a 
different demyelination pattern through the corpus callosum (Stidworthy et al, 2003). 
However, no major differences in susceptibility to cuprizone between these two 
regions were apparent in the present study. An anti-inflammatory effect of EPO in 
oligodendrocyte cultures has been reported before (Genc et al, 2006) and is in 
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agreement with the general anti-inflammatory effect of EPO in several different 
models such as EAE (Agnello et al, 2002; Li et al, 2004), cortical lesions (Sargin et 
al, 2009), epilepsy (Jung et al, 2011), closed head injury (Yatsiv et al, 2005) and 
ischemia (Villa et al, 2003). The search for further mechanistic insight into EPO 
action in the cuprizone model related to cytokines or microglial activity markers failed 
to show any clear beneficial effect. This may result from several limitations of the 
cuprizone model (as discussed below) and from limitations of the available material 
for this analysis. The mRNA analysis was based on whole brain sections from 
perfused mice. Either native brain samples and/or a brain region-specific expression 
analysis of these markers could show a clearer result in this analysis.  
Early axonal degeneration induced by cuprizone could be counteracted by EPO. So 
far, an effect of EPO on APP accumulation has not been reported. The EPO effect on 
axonal degeneration can either be direct or indirect via a reduction of the number of 
microglia. The anti-inflammatory and axon protective effect of EPO may explain, at 
least partly, better myelin preservation (%MTR) and better performance in the beam 
balance task. 
 
In summary, this study showed that EPO improved the performance in the beam 
balance task and reduced or protected the severe enlargement of the ventricular 
system. Additionally, EPO reduced the number of microglia and for the first time, was 
found to reduce axonal degeneration in brain white matter tracts. 
 
4.4 Limitations of the model  
 
By carefully reviewing the cuprizone literature, one gets the impression that this 
model is well characterized and has only a few limitations. Indeed, the model is well 
characterized, especially concerning changes on the immunohistochemical level. 
However, in the presented experiments several difficulties became obvious that were 
not evident from the literature. (1) The model shows high variability, which became 
especially clear not only from the MRI but from the histological analysis as well. High 
within-group variability was observed. One reason for the variations could be the 
method of cuprizone application. The actual intake of cuprizone is dependent on how 
much they eat and therefore can vary a lot between the mice. Moreover, the aspect 
that cuprizone might be taken up via skin or respiration is an additional factor which 
may further raise the chances of variability. Especially regarding treatment trials, a 
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high variability means that a high number of mice need to be used for solid 
conclusions. The application of cuprizone via injections would be the most precise 
method of administration but is not reported so far. (2) The observation of intrinsic 
remyelination and a general fast recovery potential by the withdrawal of cuprizone in 
this model makes it difficult to predict the optimal time point for investigation. In this 
thesis it became clear that some effects of EPO may have been overlooked due to 
the possible lack of analyses at the optimal time points. A detailed analysis of a time 
series would be necessary but is animal consuming and labor intensive. Moreover, 
the fast recovery makes at least the investigation of treatment trials concerning 
neuroregeneration difficult. (3) Final conclusions of studies using the cuprizone 
model for pharmacological studies are limited because the mechanism of cuprizone 
damage on oligodendrocytes is not yet fully understood and subject to investigation 
(Liu et al, 2010).  
 
4.5 Final conclusion 
 
As outlined before, there are several limitations of the cuprizone model which should 
be carefully considered, especially before using this model for pharmacological trials 
in the future. For the first time, different aspects of EPO action on cuprizone-induced 
de- and remyelination were investigated in this thesis. In general, repeated cuprizone 
feeding was for the first time induced in C57BL/6 mice and showed a physical 
robustness (rota-rod and body weight) of the mice at the end-point of the experiment. 
However, from the myelin protein analysis, imaging readouts and beam balance 
performance, it could be speculated that the recovery potential of the model is either 
limited upon repeated cuprizone exposure or still has a high recovery potential. To 
clarify this aspect, analyses at several more time points would be needed. No major 
EPO effects were found in this experimental set-up. On the other hand, by 
investigating the effect of EPO on demyelination, a surprisingly clear protective effect 
of EPO was detectable even if not all readouts always reached clear significance. 
EPO ameliorated clinical readouts such as beam balance performance and 
enlargement of the ventricular system, which may partially be explained by a 
reduction of inflammation-associated axonal degeneration in the corpus callosum.  
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